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ABSTRACT 
 
 The first part of this thesis deals with the syntheses of ovalicin and its analogues. 
Ovalicin inhibits the endothelial cell proliferation. Apart from being anti-angiogenic it 
also exhibits antibiotic, antitumor, and immunosuppressive properties. Unlike other 
syntheses, we started with an acyclic compound, ethyl propiolate (1.66). Our flexible 
route towards the synthesis used intramolecular Heck cyclization reaction to construct an 
appropriately functionalized 3-methylene-6-(tert-butyldimethylsilyloxy)cyclohexene 
(1.63) from 1.66 in four steps. A number of synthetic analogues were synthesized via this 
strategy. Upon selective epoxidation and dihydroxylation of 1.63, a mixture of diols 
(3S*,4R*,5S*,6S*)-6-(tert-butyldimethylsilyloxy)-1-oxaspiro[2.5]octane-4,5-diol (1.107) 
and (3S*,4S*,5R*,6R*)-6-(tert-butyldimethylsilyloxy)-1-oxaspiro[2.5]octane-4,5-diol 
(1.108) were obtained. Subsequent functional group transformations of diols 1.107 and 
1.108 gave ketones (3S*,4S*,5R*,6R*)-6-(tert-butyldimethylsilyloxy)-5-methoxy-1-
oxaspiro[2.5]octan-4-one (1.112) and (3S*,5S*,6S*)-6-(tert-butyldimethylsilyloxy)-5-
methoxy-1-oxaspiro[2.5]octan -4-one (1.117). Addition of vinyl lithium to the ketones 
followed by functional group transformation gave ovalicin analogues. Several 
intermediates were subjected to biological activity test for inhibition of growth of T. 
brucei. Our synthetic efforts towards the synthesis of ovalicin are discussed. 
 The second part of my thesis deals with the synthesis of different tricyclic pyrone 
(TP) analogues which inhibit the aggregation of Aβ peptides. Alzhemier’s disease (AD) 
is caused by accumulation of fibrillar amyloid deposits in the AD brain. We synthesized a 
series of tricyclic pyrone derivatives and evaluated their counteraction on amyloid 
toxicity. TP analogue, (5aS,7S)-7-[(1R) and (1S)-2-(N3-adenyl)-1-methylethyl]-3-methyl-
1H,7H-5a,6,8,9-tetrahyro-1-oxopyranol[4,3 -b] [1] benzopyran (CP2) is nontoxic, small 
and permeable molecule prevents the death of human neuroblastoma MC65 cells that 
conditionally expressed SβC gene. We further found that CP2 ameliorates the toxicity 
and inhibits the formation of Aβ oligomeric complexes. Binding studies using surface 
plasma resonance and atomic force microscopy studies suggest that CP2 permeates into 
the cells and interacts with Aβ peptides and inhibits the Aβ oligomerization. To 
understand the mechanism of Aβ aggregation and toxicity, CP2 and its derivatives are 
  
synthesized to evaluate their action. The key intermediate in the synthesis of CP2 is 
(5aS*,7S*)-7-[(1R*) and (1S*)-2-bromo-1-methylethyl]-3-methyl-1H,7H-5a,6,8,9-
tetrahyro-1-oxopyranol[4,3-b][1] benzopyran (2.9), which in turn can be prepared from 
our previously reported method. Our aim is to synthesize a series of compounds and 
investigate the biological activities of different TP analogues. 
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also exhibits antibiotic, antitumor, and immunosuppressive properties. Unlike other 
syntheses, we started with an acyclic compound, ethyl propiolate (1.66). Our flexible 
route towards the synthesis used intramolecular Heck cyclization reaction to construct an 
appropriately functionalized 3-methylene-6-(tert-butyldimethylsilyloxy)cyclohexene 
(1.63) from 1.66 in four steps. A number of synthetic analogues were synthesized via this 
strategy. Upon selective epoxidation and dihydroxylation of 1.63, a mixture of diols 
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(1.108) were obtained. Subsequent functional group transformations of diols 1.107 and 
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methoxy-1-oxaspiro[2.5]octan -4-one (1.117). Addition of vinyl lithium to the ketones 
followed by functional group transformation gave ovalicin analogues. Several 
intermediates were subjected to biological activity test for inhibition of growth of T. 
brucei. Our synthetic efforts towards the synthesis of ovalicin are discussed. 
 The second part of my thesis deals with the synthesis of different tricyclic pyrone 
(TP) analogues which inhibit the aggregation of Aβ peptides. Alzhemier’s disease (AD) 
is caused by accumulation of fibrillar amyloid deposits in the AD brain. We synthesized a 
series of tricyclic pyrone derivatives and evaluated their counteraction on amyloid 
toxicity. TP analogue, (5aS,7S)-7-[(1R) and (1S)-2-(N3-adenyl)-1-methylethyl]-3-methyl-
1H,7H-5a,6,8,9-tetrahyro-1-oxopyranol[4,3 -b] [1] benzopyran (CP2) is nontoxic, small 
and permeable molecule prevents the death of human neuroblastoma MC65 cells that 
conditionally expressed SβC gene. We further found that CP2 ameliorates the toxicity 
and inhibits the formation of Aβ oligomeric complexes. Binding studies using surface 
  
plasma resonance and atomic force microscopy studies suggest that CP2 permeates into 
the cells and interacts with Aβ peptides and inhibits the Aβ oligomerization. To 
understand the mechanism of Aβ aggregation and toxicity, CP2 and its derivatives are 
synthesized to evaluate their action. The key intermediate in the synthesis of CP2 is 
(5aS*,7S*)-7-[(1R*) and (1S*)-2-bromo-1-methylethyl]-3-methyl-1H,7H-5a,6,8,9-
tetrahyro-1-oxopyranol[4,3-b][1] benzopyran (2.9), which in turn can be prepared from 
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                     oligomer of size 40 nm. 
Figure 2.41 Cortical neurons were treated with different concentrations of Aβ42  
                     oligomers. Data is shown as percentage viability after 48 hr treatment with  
                     Aβ42 oligomers. 
Figure 2.42 Cortical neurons treated with Aβ monomers (M) and oligomers (O) in          
                     presence of CP2 (50 nM)and TP17 (50 nM). 
Figure 2.43 Structures of quinoline compounds. 
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CHAPTER 1 – Synthesis of Ovalicin and its Analogues 
 
1.1 Introduction 
 
Cancer is the second major cause of death, responsible for 2.5 million deaths every year 
in western countries.1, 2 Over the years researchers developed a number of methods to treat 
cancer and a number of experimental treatments are evolving day by day. Currents methods like 
chemotherapy, radiation therapy and surgery are effective therapies to treat cancer. An approach 
to interrupt the tumor induced angiogenesis was first proposed by J. Folkman to treat cancer.3, 4  
Angiogenesis is a process of involving the growth and formation of new blood vessels 
which plays an important role in healing wounds and repairing damaged tissues.5 Angiogenesis 
plays a vital role in the growth of tumors.5 Tumor cell requires nutrients and oxygen supply from 
the vascular system.1, 5 So this strategy of inhibiting angiogenesis is proved to be an effective 
procedure to arrest the growth of tumor. Anti-angiogenic drugs (AAD) suppress the growth of 
tumor by inhibiting the growth of blood vessels, on which these cancer cells survive and grow.6 
Many of these drugs work by attacking the vascular endothelial growth factor (VEGF) pathway 
and some attach on the VEGF receptor.6 Unlike chemotherapy drugs, AAD have no or less side 
effects. Side effects like bleeding in digestive tracts and increase in blood pressure are no 
exception.6 In some cases AAD will shrink tumors and in some cases they will suppress the 
growth of tumors and will not allow them to grow further.6 Patients with different physiological 
states may take varied time periods for treatment and some may even require long term treatment. 
The combination of AAD and chemotherapy drugs proved to be successful in some cases.6  
Natural products such as fumagillin and ovalicin were discovered to be potential anti-
angiogenic sesquiterpene compounds due to their “inhibition of endothelial cell proliferation”.1, 5 
Ovalicin (IC50 = 0.4 nM against human MetAP2)7and fumagillin are structurally similar 
compounds (Figure 1.1). TNP-470, O-(chloroacetylcarbamoyl)fumagillol is a synthetic 
derivative of fumagillin, is less toxic and more active than fumagillin with an IC50 value of 1.0 x 
10-9 M against human MetAP2.7, 8 TNP-470 is already in clinical trials used for treatment of 
cancers such as prostrate, kidney etc.1 Like any other drugs, because of the presence of active 
functional groups, TNP-470 shows side effects like ataxia, vertigo, drowsiness and agitation.1  
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 Ovalicin, structurally similar to fumagillin is isolated from fungus Pseudorotium ovalis.9, 
10 Ovalicin has a tert-hydroxy group at C-4 and a keto group at C-6, which not only differs in 
structure but also in activity with fumagillin. Ovalicin is stable at room temperature and remains 
crystalline for at least two years with no trace of decomposition whereas fumagillin decomposes 
gradually at room temperature.8 Apart from being anti-angiogenic it also exhibits antibiotic, 
antitumor and immunosuppressive property.5, 11, 12 The activity of ovalicin is comparable to TNP-
470. “Both ovalicin and TNP-470 inhibit the proliferation of endothelial cells”.5 But it is not yet 
found whether the mode of action is the same for both compounds.5 
 Recently, the antimicrosporidial activity of these sesquiterpene compounds was 
demonstrated by Didier and coworkers.13 More common microsporidia that infect humans are 
Enterocytozoon bieneusi, Encephalitozoon intestinalis, Encephalitozoon cuniculi and 
Encephalitozoon hellem.13 Currently albendazole is used to treat microsporidia infections in 
humans.13 Fumagillin, TNP-470, ovalicin and ovalicin derivatives are screened in vitro on 
Encephalitozoon intestinalis and Vittaforma corneae assays and they were shown to inhibit the 
replication of these strains.13 The authors found several synthetic analogues of ovalicin 
possessing greater activities. Trypanosoma brucei, parasitic protozoa causes sleeping sickness, 
malaria and other diseases.14  Trypasonoma brucei contains a class of methionine 
aminopeptidases (MetAP2) enzymes.15 Inhibition of this enzyme will result in death of the 
parasite. Ovalicin, an inhibitor of angiogenesis, is believed to be lethal to Trypasonoma brucei 
protozoa. We tested a series of ovalicin intermediates and the activities are discussed in the later 
part of this thesis. 
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 Methionine aminopeptidases (MetAPs) specifically releases methionine residues from 
proteins. They exist in two types MetAP1 and MetAP2.16  Addlagatta and Matthews reported 
MetAP2 as the molecular target for sequiterpenes like ovalicin and fumagillin. Both fumagillin 
and ovalicin have reactive epoxide groups which can coordinate and modify MetAP2.17 To know 
which epoxide is more vital for the activity of these compounds, a number of analogues were 
synthesized with and without the epoxides. It was shown that the spiroepoxide is important and 
the side chain epoxide is not required for bioactivity.17 It was also reported that the low affinity 
of these compounds was due to sterically hindered site in MetAP1.18 This spiro epoxide binds to 
the MetAP and reacts with the histidine residue His(231), an active enzyme site (shown in the 
following equation 1).18 It was determined by x-ray structure that fumagillin binds to His231 in 
MetAP2.18 
 
O O
H
OMe
OR
N NH
His231 H+
OH O
H
OMe
OR
N N
His231
eq 1
 
 
1.2 Previous reported total synthesis 
1.2.1 Corey’s Synthesis 
The first total synthesis of (±)-ovalicin was reported by E. J. Corey et al. in 1985.19 Five 
total syntheses this compound sprouted up to date.19-23 Though Corey’s group synthesized 
fumagillin24 earlier to the syntheses of ovalicin, they employed a completely different synthetic 
strategy for the synthesis of ovalicin. The design of this synthesis started with an epoxy enone 
from 2,4-dihydroxybenzoic acid and a stereoselective addition of a trisubstituted olefins resulting 
in an internally stereospecific epoxidized product which subsequently gave racemic ovalicin. 
Reaction of 2,4-dihydrobenzoic acid (1.1) with methyl iodide and potassium carbonate 
yielded methyl 2-hydroxy-4-methoxybenzoate (1.2) in 83% yield and an immediate reduction 
with sodium bis(2-methoxyethoxy)aluminum dihydride gave phenol 1.3 in 97% yield (Scheme 
1.1). Phenol was oxidized with aqueous solution of sodium periodate to give dienone epoxide 1.4 
in 61% yield. Attempts to reduce γ,δ double bond selectively failed resulting in regeneration of 
 4
phenol 1.3. However reduction was carried out following the procedure laid by Adam and 
Eggelte25 by adding acetic acid and potassium azodicarboxylate. Diimide was generated in situ 
which reduces the γ,δ double bond to give epoxy enone 1.5 in 77% yield.19 
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Scheme 1.1
  
The next step is the addition of alkenyllithium reagent to the epoxy enone 1.5. The 
preparation of alkenyllithium involves Shapiro reaction (the conversion of ketones to 
sulfonylhydrozones is known as Shapiro reaction) and its addition to 1.5 provided an 
intermediate for subsequent epoxidation. Compound 2,4,6-triisopropyl benzene (1.6) when 
treated with chlorosulfonic acid gives 2,4,6- triisopropylbenzenesulfonyl chloride (1.7) which 
reacts with hydrazine gave 2,4,6- triisopropylbenzenesulfonyl hydrazine (1.8). Acetone when 
treated with compound 1.8 gave acetone 2,4,6- triisopropylbenzenesulfonyl hydrazone (1.9).26, 27 
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The solution of 1.9 and DME was cooled to -78 0C, and n-butyllithium was added to the 
mixture and allowed to reach -66 0C over 20 min. Then 1-bromo-3-methyl-2-butene (1.10) was 
added to the reaction mixture, and the temperature was maintained at -66 0C over a period of 20 
minutes. N’,N’-Tetramethylethylenediamine (TMEDA) was added to stabilize the anion formed 
at -78 0C followed by another equivalent of  n-butyllithium. The reaction mixture vessel was 
allowed to warm to -3 0C over a period of 2 hours to obtain alkenyllithium reagent 1.11. 
Compound 1.11 when treated with tri-n-butyltin chloride at -78 0C gave alkenyltin reagent 1.13. 
The conversion of 1.13 to 1.12 can be carried by treatment of alkenyltin 1.13 followed by iodine 
(Scheme 1.2). Alkenyliodide 1.12 in ether was treated with tert-butyllithium at -78 0C, and to 
this reaction mixture epoxy enone 1.5 was added. A mixture of diastereomers 1.14 and 1.15 were 
obtained (Scheme 1.3). The addition reaction provided an intermediate, which can be converted 
to the epoxidized product through a stereoselective oxidation reaction.19  
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 Reaction of 1.14 with N-bromosuccinimide (NBS) in methanol gave bromo ketal 1.16. 
Compound 1.16 was treated with p-toluenesulfonic acid in acetone-water system to yield bromo 
ketone 1.17 in 94%. Bromo ketone 1.17 on treatment with hydroxylamine and potassium acetate 
for one hour gave bromo oxime 1.18. Treatment of oxime 1.18 with triethylamine and methanol 
gave methoxy oxime 1.19 in greater than 90% yield.  Hydrolysis of methoxy oxime 1.19 was 
performed in presence of titanium trichloride and methanol. Aqueous ammonium acetate served 
as a buffer in this conversion to yield a mixture of diastereomers 1.20 and 1.21 (Scheme 1.4). 
The characterization of these diasetreomers was performed by 1H NMR spectroscopy.19 
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 Compound 1.20 was isomerized to 1.21 using potassium carbonate in presence of 
methanol. The conversion of compound 1.21 to ovalicin involves allylic epoxidation using 
vanadyl acetylacetonate along with tert-butylhydroperoxide in toluene (Scheme 1.5). Thus 
synthesized ovalicin was identified using 1H NMR, IR, mass , 13C NMR spectroscopy and found 
no different from the authentic sample.19 
 
Scheme 1.5
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Few years later, Corey et al. modified the original synthetic strategy and came up with a 
short enantioselective route using catalytic asymmetric dihydroxylation to synthesize ovalicin in 
large scale.28 The key step in this strategy was the synthesis of a chiral intermediate 1.22. 
Synthesis of ovalicin from this intermediate 1.22 followed the above cited procedure.19 The 
esterification of readily available allylic alocohol 1.23 was carried with p-methoxybenzoyl 
chloride to give p-methoxybenzoate ester (1.24) in 98% yield. Intermediate 1.24 was considered 
to be a good substrate for OsO4-biscinchona alkaloid catalyzed dihydroxylation. Compound 24 
when treated with K2OsO4 (1 mol %), (DHQ)2PHAL (1 mol %), K3FeCN6, K2CO3 and 
CH3SO2NH2 in t-BuOH-H2O mixture, a dihydroxylated product 1.25 was obtained after 4 hours 
in 93% yield and 99% enantiomeric excess. Swern oxidation of intermediate 1.25 gave ketone in 
87% yield, further treatment of this ketone with p-toluenesulfonic acid afforded β-methoxy α,β–
enone 1.26 in 93% yield. Ester cleavage of 1.26 was carried out using K2CO3 followed by 
mesylation with methanesulfonyl chloride gave compound 1.27. Treatment of compound 1.27 
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with aqueous NaOH gave compound 1.22, a key intermediate for the synthesis of ovalicin 
(Scheme 1.6).28 
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1.2.2 Barton-Quiclet-Sire-Samadi synthesis 
 Ovalicin and several other analogues were synthesized from a naturally occurring 
optically active cyclitol L-quebrachitol.20 L-Quebrachitol was isolated from Hevea brasiliensis, 
considered to be a perfect compound. It has a methoxy group at C-2 and absolute 
stereochemistry required for conversion to ovalicin. This synthetic strategy slightly varies form 
the strategy reported by the same group29 in 1994. 
 L-Quebrachitol on treatment with cyclohexanone and p-toluenesulfonic acid gave 1L-
3,4:5,6-di-O-cyclohexylidene-2-O-methyl-chiro-insitol, further treatment with benzyl bromide 
gave 1.28. The less stable trans ketal was cleaved readily using ethylene glycol in presence of p-
toluenesulfonic acid to give a diol 1.29 in 70% yield. The diol was treated with acetic anhydride 
to give diacetylated product 1.30 in 98% yield. Deprotection of cis-ketal gave a crystalline diol 
1.31 in 77% yield (Scheme 1.7).20 Diol 1.31 was treated with thiophosgene (Corey-Winter cis-
deoxygenation) and DMAP to give a thiocarbonate 1.32. Compound 1.32 when heated to 120 0C 
with trimethyl phosphite gave a cyclohexene 1.33. Removal of acetate groups in 1.33 was 
acheived using methanol ammonia solution to give ene-diol 1.34 in 82% yield. Selective 
oxidation of allylic alcohol was performed using MnO2 to give enone 1.35 in 50% yield.20 
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 Compound 1.35 was a key intermediate in synthesis of (-)-ovalicin. The path to the 
synthesis of ovalicin followed Corey’s strategy.19 Hydrogenation of 1.35 using catalytic amount 
of palladium in ethanol afforded hexanonediol 1.36 in 85% yield. Selective benzylation of α-
hydroxy alcohol and silylation of the γ-alcohol gave ketone 1.37. The ketone was converted to an 
exocyclic olefin using a Wittig reagent, methylenetriphenylphosphorane to compound 1.38. 
Oxidation of 1.38 was carried by using meta-chlorobenzoic acid (MCPBA). Epoxidation of exo 
double bond of 1.38 afforded a mixture of spiroepoxy isomers 1.39 (84%) and 1.40 (10%) 
(Scheme 1.8).20  Swern oxidation of 1.39 gave epoxy ketone 1.41 in 88% yield. The synthesis of 
alkenyl side chain followed Corey’s procedure19, and addition of side chain to compound 1.41 
gave exclusively one compound 1.42 in 75% yield. In this case the bottom face is being blocked 
by silyl group and methoxy group, allowing the side chain to come from the top face to give only 
one isomer. Sharpless epoxidation of adduct 1.42 using tert- butyl hydroperoxide and vanadium 
acetylacetonate yielded mixture of epoxides 1.43 and 1.44. This mixture can be separated using 
silica gel column. Alcohol 1.43 was oxidized using pyridinium dichromate (PDC) to give (-)-
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ovalicin in 78% (Scheme 1.9).20 Thus synthesized (-)-ovalicin was characterized and matched to 
naturally occurring ovalicin.20 
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 1.2.3 Hayashi Synthesis 
 
Another total synthesis was reported recently in 2006 by Hayashi et al.21  Apart from 
synthesis of ovalicin their methodology was used to synthesize structurally similar compounds 
which belong to both the families of ovalicin and fumagillin (Figure 1.2). Herein authors 
developed proline-mediated α-aminoxylation of carbonyl compounds as a key step for the 
synthesis of RK-805 (isolated from fungus Neosartorya sp.), fumagillol, FR65814 (an 
immunosuppressant agent), ovalicin and 5-demethylovalicin.21 
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 The synthesis of ovalicin starts with α-aminoxylation of 1,4-cyclohexanedione 
monoethylene ketal 1.45 using L-proline with a gradual addition of nitrosobenzene over 24h at 0 
0C to give optically pure R-α-aminooxylated  cyclohexanone 1.46 in 93% yield.21 Reductive 
elimination of N-O bond in 1.46 was performed using H2 at atmospheric pressure and catalytic 
amount of Pd/C to give 1.47. After several experiments the authors found out that the cyanation 
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followed by silylation of compound 1.47 gave a highly diastereoselective compound 1.48 but in 
low yields. The reduction of cyanide 1.48 to aldehyde 1.49 was performed using 
diisobuytlaluminium hydride (DIBAL-H) (Scheme 1.10).21  
 Further reduction of aldehyde 1.49 to alcohol 1.50 was carried using DIBAL-H. 
Intermediate 1.50 was converted to a spiroepoxide alcohol 1.51. The total yield of conversion 
from 1.49 to 1.51 is 81%. Oxidation of alcohol 1.51 using Dess-Martin periodinane (DMP) 
followed by treatment with tert-butyldimethylsilyl chloride (TBSCl) gave cyclohexenone 1.52 in 
60% yield. Substituted alkenyl bromide 1.53 addition to cyclohexenone epoxide 1.52 gave an 
adduct 1.54 in 91% yield. This addition is highly diastereoselective. Since this side chain was 
highly unstable and reactive, conversion to an epoxide 1.55 using a vanadium reagent along with 
tert-butylhydrogen peroxide (TBHP) was carried out quickly. The obtained compound 1.55 is 5-
demethylovalicin (also a potent anti-angiogeneic inhibitor). The traditional methods of 
conversion of 5-demethylovalicin to ovalicin failed. Authors finally adapted a strategy by 
modifying Corey’s method.19 Alcohol 1.55 was protected with pivaloyl chloride and ketone 1.56 
was transformed to an oxime 1.57.  Deprotection of pivaloyl group with K2CO3 and methanol 
gave a compound 1.58. The oxime 1.58 was converted to ovalicin in good yield (Scheme 1.11).21 
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 Two other total syntheses of ovalicin were reported by other researchers22, 23 which are 
not discussed in this thesis.  
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1.3 Synthesis of Ovalicin 
1.3.1 Retrosynthetic analysis 
The target molecule ovalicin, a sesquiterpene comprises a cyclohexane ring with five 
stereogenic centers of which three of them are on the ring, two epoxides of which one is a spiro 
epoxide, a substituted olefin and a ketone.21 Other researchers, as discussed in earlier sections 
started with a core six-membered ring compounds (substituted phenols, naturally occurring 
stereo-defined cyclohexane ring compounds, etc) as starting materials. We used a simple non-
cyclic compound, ethyl propiolate to originate our synthetic scheme. A novel approach to 
synthesize a functionalized six membered ring was achieved via intramolecular Heck cyclization 
and a regioselective epoxidation are the key steps in our synthetic scheme. Generation of 
diastereomers in due course of our synthetic strategy led us to use this route to access a range of 
simpler and stable analogues for bioevaluation. The retrosynthesis of ovalicin is outlined in the 
following schemes. The later part of this total synthesis i.e. addition of the side chain and 
modifications on the cyclohexane ring follows the Corey19 and Barton20 strategy (Scheme 1.12). 
The addition of side chain is stereoselective, coming from the opposite side of the methoxy and 
silyloxy groups and these methoxy, silyloxy groups have to be cis to each other in compound 
1.60 (Scheme 1.12). Stereochemical inversion is unavoidable in these groups if they are not cis 
to each other and is discussed later in this thesis. The synthesis of trisubstituted olefin was 
reported by Adlington and Barrett.26, 27 This was converted to alkenyl lithium reagent, a very 
reactive species to react with the ketone in compound 1.60 (similar compound 1.41 was reported 
by Barton and coworkers20). Functional group transformations such as sharpless epoxidation, 
deprotection and oxidation are performed from compound 1.59 to obtain final product ovalicin.  
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 Synthesis of a structurally similar compound to 1.60 was already reported by Barton.20 
Naturally occurring compound with defined stereochemistry20, substituted phenols19 and 
functional group substituted cyclohexane rings21 were proven to be essential starting materials to 
synthesize ovalicin. In our case none of those starting materials were used to synthesize 
compound 1.60. Instead we obtained this compound by a series of transformations from a readily 
available alkyne ethyl propiolate (1.66). Ketone 1.60 was obtained from diol 1.61. Methylation 
followed by oxidation of 1.61 yields ketone 1.60. The diol 1.61 was readily obtained from 
selective epoxidation and dihydroxylation of appropriately functionalized 
methylidenecyclohexene 1.63. The key steps in our total synthesis are the utilization of Heck 
reaction in construction of this functionalized methylidenecyclohexene 1.63 and regioselective 
epoxidation. Intramolecular Heck cyclization of 1.68 afforded methylidenecyclohexene 1.63. 
Grignard addition to aldehyde 1.65 would provide 1.68. Aldehyde 1.65 was readily obtained by 
reduction of alkyne 1.66 (Scheme 1.13). 
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1.3.2 Synthesis of methylidenecyclohexenyloxysilane (1.63) 
Synthesis of tert-butyldimethyl(4-methylenecyclohex-2-enyloxy)silane 1.63 is outlined in 
the Scheme 1.14. Commercially available ethyl propiolate (1.66) was used as the starting 
material. Authors Marek, Alexakis and Normant found out that methyl propiolate and substituted 
propiolates can be converted to (Z)-β-iodoacrylates by hydroiodination.30 This conversion was 
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regio and stereospecific.30 Dry sodium iodide and glacial acetic acid were stirred along with 
ethyl propiolate (1.66) and the resulting mixture was heated to 70 0C for 12 hours. Thus obtained 
product was distilled to get pure ethyl (Z)-β-iodoacrylate 1.67 in 89.2% yield.31 The reaction of 
iodoacrylate 1.67 with diisobutylaluminium hydride (DIBAL-H) at -78 0C gave (Z)-
iodoacrylaldehyde 1.65.30, 31 Aldehyde 1.65 was quite unstable and converts to (E)-isomer upon 
long standing or at higher temperatures. Addition of freshly prepared Grignard reagent (refluxing 
4-bromo-1-butene with magnesium in THF at 85 0C for 2 hours gave Grignard reagent) to 
aldehyde 1.65 gave an iodoalcohol 1.68 (a racemic mixture) without any stereoselectivity. We 
did not obtain an enantio pure 1.64. Iodoalcohol 1.68 was obtained in 74% yield. The side 
products of the this reaction were both (E)- and (Z)- isomers of 3-iodoprop-2-en-1-ol. 
Iodoalcohol 1.68 was protected with tert-butyldimethylsilyl chloride (TBDMSCl).24 The reaction 
was carried in presence of base imidazole and a catalytic amount of 4-dimethylaminopyridine 
(DMAP) in dimethylforamide (DMF) and stirred for 12 hours at room temperature to give 98% 
yield of 1.69.32, 33 Intramolecular Heck cyclization was performed to obtain a cyclized compound 
1.63 (a racemic mixture) not an enantiopure compound 1.70. This intramolecular Heck 
cyclization was studied by a graduate student James McGill earlier in our laboratory.34 He 
optimized the reaction conditions, found out suitable base, solvent and other reagents to obtain 
best results. Herein the same procedure was followed to obtain the cyclized product from 1.69. 
This silyl protected iodo compound was treated with palladium acetate, silver phosphate, 
triphenylphosphine and proton sponge in presence of dimethylforamide (DMF) and the reaction 
mixture was heated to 50 0C for 7 hours to obtain 93% yield of cyclized product 1.63. A doublet 
assigned to C2 hydrogen at δ 6.1, δ 5.7 for C1 hydrogen and a doublet at δ 4.8 for C7 hydrogen 
in proton NMR spectra confirms the cyclization of the product 1.63. Attempts were made to 
cyclize the unprotected alcohol 1.68. Cyclized alcohol was obtained in low yields and generation 
of side products was inevitable. 
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1.3.3 Epoxidation of methylidenecyclohexanesilane 1.63 
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Epoxidation of 1.63 was initially carried out using meta-chloroperbenzoic acid (MCBPA) 
as an oxidizing agent (Scheme 1.15). Initially the reaction was carried out with 1 equivalent of 
MCBPA in CH2Cl2 at 0 0C. New spots were discovered on thin layer chromatography (TLC) and 
one of which was assumed to be the desired product. Subsequently on column chromatography 
(CC) the new spots weren’t collected. Assumptions were made that new spots formed on TLC 
were decomposed on silica gel column chromatography. It is possible that in situ generated 
meta-chlorobenzoic acid, decomposes the desired epoxide. So as to neutralize the thus formed 
meta-chlorobenzoic acid, 2 equivalents of NaHCO3 were added to the reaction mixture. The 
problem of decomposition could not be avoided. Reagents like sodium fluoride and potassium 
fluoride were also used along with MCPBA,35 however only decomposed by-products were 
detected from nuclear magnetic resonance (NMR) spectrum of the crude product. Different 
solvent systems and varied reaction times didn’t provide desired spiro epoxide. Other oxidizing 
agents were in search to overcome the problem.  
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Dioxiranes are neutral oxidizing reagents reported by Shi et.al36 for asymmetric 
epoxidation of olefins. Dioxiranes were produced in situ from oxone (potassium 
peroxomonosulfate) and chiral ketones.36 A few chiral ketones 1.72-1.76 are listed below.37 High 
yields and enantiomeric excess are noticeable features of this oxidation.36-38 
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Chiral ketone wasn’t used to oxidize 1.63 instead readily available cyclohexanone was 
used. Following the procedure cited by Shi,38 compound 1.63 was mixed with cyclohexanone. 
To this mixture dipropylene glycol dimethyl ether (DMM), acetonitrile, aqueous K2CO3, acetic 
acid and catalytic amount of Bu4NHSO4 were added. This mixture was cooled to -10 0C. A 
solution of oxone-EDTA and aqueous K2CO3 was added to the above mixture. The reaction was 
stirred for 3 hrs at -10 0C. The TLC analysis shows the formation of product. The reaction was 
worked up and without further purification the crude material was treated with OsO4 for 
dihydroxylation. After column chromatography about 5% of desired diol 1.61 was obtained. Use 
of chiral ketone might have increased the yield of this reaction. A different kind of dioxirane was 
used to obtain the spiro epoxide in high yields and is discussed in later parts of this thesis. 
1.3.4 Changing the protection group from silyl to benzoyl 
In our previous attempts the generation of meta-chlorobenzoic acid was affecting the silyl 
group resulting in low yields or absence of desired product. In order to overcome this problem 
benzoyl protecting group was replaced to silyl protecting group. The cleavage of tert-
butyldimethylsilyl (TBDMS) group was achieved by treating 1.63 with tetrabutylammonium 
fluoride (TBAF) in tetrahydrofuran (THF) at 0 0C for 10 hours. The progress of the reaction was 
monitored by TLC. On completion of the reaction, no work up was performed. The alcohol 1.77 
was protected with benzoyl chloride. To the alcohol 1.77, benzoyl chloride (C6H5COCl) and 
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triethylamine (Et3N) were added at 0 0C. Warming up the reaction to room temperature and 
allowing the reaction to stir for 10 hours afforded benzoyl protected diene 1.78 in 98% yield 
(Scheme 1.16). Epoxidation of 1.78 with MCBPA led to no decomposition of the product. 
Therefore benzoyl protecting group was considered to be the best for this scheme.  
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1.3.5 Epoxidation followed by dihydroxylation 
Changing the protecting group from silyl to benzoyl was a major modulation in our 
synthetic scheme. Experiments in this section were carried out by Kaiyan in our group. He 
played a major role in separation and identification of the diol intermediates 1.81 ~ 1.83 (Scheme 
1.17). The benzoyl protected diene 1.78 was oxidized using MCPBA as an oxidizing agent in 
presence of sodium fluoride (NaF) and potassium fluoride (KF). The resulting epoxide was 
stable for few hours without any considerable decomposition. The progress of the reaction was 
monitored by TLC. The organic layers were washed with sodium thiosulfate (to remove any 
excess oxidizing agents), dried over anhydrous sodium sulfate and concentrated. The NMR 
spectrum of the crude product confirms the formation of the product. This epoxide wasn’t 
purified by column chromatography. Moreover this oxidation was not stereoselective. Both 
isomers 1.79 and 1.80 were formed. Without any further delay this mixture of ene-epoxides was 
treated with osmium tetraoxide (OsO4), N-methylmorpholine-N-oxide (NMO) in the presence of 
tert-butanol and acetone-water system as a solvent.39 Three inseparable diastereomers were 
formed 1.81, 1.82 and 1.83 in 5:4:1 ratio (based on integration in crude proton NMR spectrum). 
The assignments of the stereochemistry were based on NMR J-couplings of the materials. 
Kaiyan was not able to separate these isomers. Appropriate solvent system to separate these 
isomers was not found (Scheme 1.17). 
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The three diols were identified by proton NMR spectra. Our assumptions were based on 
the coupling constants and coupling patterns and the structure of 1.84. Compound 1.84 was 
obtained from a silylation reaction as described in scheme 1.18 (vide infra). The structure of the 
compound 1.84 was identified by a single crystal X-ray analysis. Compound 1.84 on desilylation 
regenerated pure diol 1.81. Thus the structure of 1.81 was confirmed.  
 
Compound 1.81 
O
H
OH
PhOCO
H
H
O
H
H
H
1
2
3
4
5
6
7
  
The proton NMR spectrum of the compound 1.81 shows signals at δ 8.06 (m, 2H), 7.59 
(m, 1H) and 7.46 (m, 2H) for benzoyl group. Shifts at δ 5.35 is assigned to C6-H and appears as 
triplet of a doublet with J values of 8 Hz and 4 Hz respectively, which correspond to the coupling 
between C6-H and C5-H (J = 8Hz, axial-axial coupling), C6-H and C7-H (J = 8Hz, axial-axial 
coupling) and C6-H and C7-equatorial H (J = 4 Hz, axial-equatorial coupling). The intensities of 
the triplet-doublet resonance in the spectrum show 1:1:2:2:1:1. The coupling constant of 8 Hz 
suggests an axial-axial coupling. So the coupling constant of 8 Hz suggests that C6-H is oriented 
at the axial position Moreover the osmium tetraoxide dihydroxylation is a syn addition.  So the 
two OH groups at C4 and C5 are cis. Because C5-OH is equatorial, consequently C4-OH is axial. 
 
Compound 1.82 
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Compounds 1.82a and 1.81 differ in the position of epoxide. The C3-O bond is axial in 
1.81 and equatorial in 1.82a. Both 1.82 and 1.82a are enantiomers, so both the compounds show 
same δ values. The signals at δ 8.06, 7.59 and 7.46 for compound 1.82 correspond to the benzoyl 
group, which are similar in compound 1.81. Since the compounds 1.81 and 1.82a differ only in 
the position of epoxide, both the compounds must show the same splitting pattern for C6-H with 
C5-H, C7-axial H and C7-equatorial H. This is confirmed by observing splitting patterns and 
coupling constants in proton NMR spectrum. Signal at δ 5.35 (for C6-H), for compound 1.82 
appears as a triplet of a doublet with J = 8 Hz and J = 4 Hz respectively. The coupling between 
C6-equatorial H with C5-equatorial H is J = 8Hz, C7-equatorial H is 8 Hz and C7-axial H is 4 Hz. 
The intensities of the triplet-doublet resonance in the spectrum show 1:1:2:2:1:1. The C2-H 
signals (doublets) at δ 2.60 and 2.86 for compound 1.82 differ from the C2-H signals (doublets) 
of compound 1.81 which show at δ 2.71 and 2.91. Thus the two compounds 1.81 and 1.82 can be 
differentiated by proton NMR spectra. 
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The proton NMR spectrum of compound 1.83 show signals at δ 8.06 (m, 2H), 7.59 (m, 
1H), 7.46 (m, 2H) for benzoyl group, which are similar to compounds 1.81 and 1.82. Signal at δ 
5.18 is assigned to C6-H and appears as doublet of a triplet with J value of 3.1 Hz and 10 Hz 
respectively. The coupling between C6-H with C7-equatorial H has a coupling constant of J = 10 
Hz (equatorial-equatorial). The coupling between C6-H and C7-axial H (equatorial-axial) and 
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with C5- axial H (equatorial-axial) has a coupling constant of J = 3.1 Hz. The intensities of the 
doublet of a triplet resonance in the spectrum show 1:2:1:1:2:1. The coupling constant of 3.1 Hz 
suggests that the C6-H is oriented at the equatorial position. Moreover osmium tetraoxide 
dihydroxylation is a syn addition. The two OH groups at C4 and C5 are cis. Since the C6-H is 
equatorial, implies that OH group at C5 is also equatorial.  
1.3.6 Separation of diols 
A novel idea was designed by Kaiyan to separate the diols 1.81, 1.82 and 1.83. The 
mixture of the diols was taken and silylation was performed using tert-butyldimethylsilyl 
chloride (TBDMSCl) with triethylamine as a base and DMAP as a catalyst (Scheme 1.18). 
Interestingly the major compound was isolated and identified by NMR spectrum and X-ray 
crystal analysis (Figure 1.4). The exact configuration of the silylated diol was unambiguously by 
X-ray single crystal analysis, which revealed the exact configuration of one diol 1.81. There 
were other silylated products formed along with compound 1.84 but are not crystalline and 
couldn’t be identified using NMR spectrum. After identifying the silylated product 1.84, it was 
desilylated and converted back to diol 1.81 (Scheme 1.18) and are used for further conversion to 
the final product, illustrated in the following sections. The X-ray crystal structure of compound 
1.84 is shown in Figure 1.4. 
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Figure 1.4 X-ray crystal structure of compound 1.84 
1.3.7 Methylation and Oxidation 
Diol 1.81 was treated with trimethyloxonium tetrafluoroborate (Me3OBF4) in the presence of 
proton sponge as a base to give a methylated product.40 This methylation was not selective, thus 
obtained a mixture of methylated compounds 1.85 and 1.86 in 1.3:1 ratio. The compound 1.85 
has the methoxy group next to the benzoyl group and they are trans to each other.  
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The proton NMR spectrum of the compound 1.85 shows signals at δ 8.06 (m, 2 H), 7.59 
(m, 1 H) and 7.47 (m, 2 H) for benzoyl group. Signal at δ 5.43 is assigned to C6-H and appears 
as triplet of a doublet with J values of 9 Hz and 4 Hz respectively. The Coupling between C6-
axial H with C5-axial H is J = 9 Hz (axial-axial coupling), C7-axial H is J = 8 Hz (axial-axial 
coupling) and C7-equatorial H is J = 4 Hz (axial-equatorial coupling). The intensities of the 
triplet of a doublet resonance in the spectrum show 1:1:2:2:1:1. The J value of 8 Hz suggests an 
axial-axial coupling. The coupling constant of 8 Hz for C6-H with C5-H confirms that C6-H is 
oriented in the axial position. Signal at δ 3.66 is assigned to C5-H and appears as a doublet of a 
doublet with J values 3.2 Hz and 7.6 Hz respectively. The coupling constant J = 3.2 Hz 
correspond to C5-axial H with C4-equatorial H and coupling constant J =7.6 Hz correspond to 
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C5-axial with C6-axail H. The coupling constant of 7.6 Hz suggest that C5-H is oriented trans to 
the C6-H.  
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The proton NMR spectrum of the compound 1.86 show signals at δ 8.07, 7.56 and 7.45 
for benzoyl group, which are similar to compound 1.85. Signal at δ 5.32 is assigned to C6-H and 
it appears as a doublet of a triplet with J values 4 Hz and 9.2 Hz respectively. The coupling of 
C6-axail H with C5-axial H is J = 9.2 Hz, C7-axail H is J = 9.2 Hz and C7-equatorial H is J = 4 
Hz. Signal at 3.99 is a doublet of a triplet is assigned to C5-H with J values of 3.2 Hz and 8 Hz 
respectively which correspond to the coupling between C5-axial H with C4-equatorial H (J = 3.2 
Hz), C6-axail H (J = 8 Hz) and C5-OH (J = 8.4 Hz). Signal at δ 2.49 is assigned to C5-OH with 
C5-H with a coupling constant of 8.4 Hz appears as a doublet. 
The two compounds 1.85 and 1.86 are differentiated by the splitting pattern of C5-axial H 
with C4-H and C6-H, a doublet of a doublet for the former and a triplet of a doublet for the later. 
 
The alcohol 1.85 was oxidized to ketone 1.87 via swern oxidation (Scheme 1.19).41 Silica 
gel column chromatographic separation was performed quickly because of fear of decomposition 
of the product on the silica gel column. The compound 1.87 was not stable. The silica gel column 
chromatography was washed with 1% triethylamine before loading the crude reaction mixture to 
avoid decomposition of the product. Thus obtained ketone 1.87 was used in next step for alkenyl 
lithium addition without any further delay. 
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1.3.8 Preparation of Alkenyl Lithium reagent 
The preparation of alkenyl lithium reagent was discussed earlier in Scheme 1.2 section 
1.2.1. 2,4,6-Triisopropyl benzene (1.6) when treated with chlorosulfonic acid at 0 0C for one 
hour afforded 2,4,6-triisopropyl benzenesulfonyl chloride 1.7 in 88% yield  after column 
chromatography. Chloride 1.7 can also be purified via crystallization using pentane as a solvent. 
2,4,6-Triisopropyl benzenesulfonyl chloride 1.7  was treated with anhydrous hydrazine at 0 0C 
for 4 hours to produce benzenesulfonyl hydrazine 1.8. The obtained benzenesulfonyl hydrazine 
1.8 was pure and needs no purification from proton NMR spectrum analysis. Moreover 
hydrazine 1.8 decomposes on column when attempted to purify. 2,4,6-Triisopropyl 
benzenesulfonyl hydrazine 1.8 was dissolved in acetone and stirred for half an hour to obtain 
benzenesulfonyl hydrazone 1.9, an application of Shapiro reaction (the synthesis of substituted 
and unfunctionalized alkenes from ketones is known as Shapiro reaction.).26, 27 This hydrazone 
can be crystallized using aqueous methanol and should be dried over P2O5. Benezenesulfonyl 
hydrazone 1.9 should be absolutely dry to prepare alkenyl lithium reagent.26, 27 Either the 
presence of acetone or water or both will quench the n-Buli, resulting in low yields of alkenyl 
lithium reagent. 
Two equivalents of n-BuLi were added to hydrazone 1.9 at -78 0C to generate a dianionic 
species 1.88. Subsequent addition of bromo compound 1.10 to the dianion gave a monoanionic 
species 1.89. N,N,N’,N’-Tetramethylethylenediamine (TMEDA) was added to stabilize the 
anionic species 1.89. Another equivalent of n-BuLi was added to 1.89 to generate a dianionic 
species 1.90. The solution of the dianionic species was a beautiful golden yellow color solution. 
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All the above intermediates are sensitive to moisture and air, and are always kept under inert 
atmosphere (argon). Intermediate 1.90 when slowly warmed to -3 0C from -78 0C, alkenyl 
lithium compound 1.11 was generated (Scheme 1.20).26, 27 Addition of alkenyl lithium 1.11 to 
ketone 1.87 was performed without any delay. 
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1.3.9 Addition of akkenyl lithium reagent to ketone 1.87 and transformation of the 
resulting adduct to ovalicin analogues 
The addition of alkenyl lithium reagent 1.11 to ketone 1.87 was no less similar to 
Corey’s19 and Barton’s20 strategy. The above prepared alkenyl lithium reagent was less stable 
and decomposes upon prolong standing. Without isolation the freshly prepared alkenyl lithium 
reagent was added to ketone 1.87.  Stereoselective addition was not observed. The addition of the 
organo lithium reagent was from both sides’ cis and anti to methoxy group. Unlike in Bartons’ 
synthesis, both the methoxy and silyl protected alcohol are cis to each other the former being 
equatorial and later being axial. In our case, the two major products were identified, 1.92 (15%) 
and 1.93 (10%). It was difficult to identify and characterize the remaining fractions from silica 
 27
gel column chromatography. Compound 1.93 was formed because the alkenyl lithum anion 
might have deprotected the benzoyl group. Compound 1.92 when treated with a base K2CO3 in 
presence of methanol deprotected the benzoyl group to give alcohol 1.93 in good yield. Alcohol 
1.93 was oxidized to ketone 1.94 using o-iodoxybenzoic acid (IBX) in DMSO.42 The final step 
was the Sharpless epoxidation, similar to that reported in Corey’s and Barton’s methodology. A 
metal-catalyzed reaction giving a selective epoxidation for olefinic alcohols was developed by 
Sharpless.43 The epoxidation of 1.94 was carried out at 0 0C in presence of vandyl acetoacetonate 
(VO(acac)2) and t-butyl hydroperoxide for 3 hours and toluene was used as a solvent. After silica 
gel column chromatographic separation and concentration of the fraction that contain the product, 
a nice crystalline compound appeared. On careful X-ray analysis, the obtained product, a 
compound 1.95, a stereoisomer of ovalicin at C2 position (Scheme 1.21). 
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Figure 1.5 X-ray crystal structure of 1.95 
1.3.10 Changing the protective group from silyl to (-)-(1S,4R)- camphanoyl 
The goal of using camphanyl chloride is to obtain an optically pure enantiomer. A chiral 
protecting group was used and tested. The silyl protecting group was cleaved and replaced with 
camphanoyl protecting group. The main reason for the choice of camphanyl chloride was to 
separate the diastereomers either by column chromatography or crystallization. The preparation 
of this compound (-)-(1S,4R)-camphanyl chloride followed a literature procedure.44 Authors 
Kappes and Gerlach described a three step procedure for the preparation of (-)-(1S,4R)-
camphanyl chloride.44 (+)-Camphoric acid (1.96) was heated with phosphrous pentachloride on 
an oil bath for 5 hr at 85 0C. Then bromine was added to the above cooled mixture and again 
heated to 65 0C for 16 hr. After a careful workup we obtained (-)-bromocamphanic anhydride 
1.97 as colorless crystals in 60% yield. Sodium carbonate and water were added to the anhydride 
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1.97 and the reaction solution was refluxed for 2 hr. The reaction mixture was neutralized with 
concentrated hydrochloric acid. Careful workup gave colorless crystals of (-)-camphanic acid 
1.98 (59% yield). Acid 1.98 was converted to colorless acid chloride, (-)-camphanoyl chloride 
1.99 using thionyl chloride in 87% yield (Scheme 1.22).44 
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 To produce the optically pure enantiomer, we planned to change the protecting group and 
replace the silyl with camphanoyl group. The alcohol was obtained on deprotecting 1.63 using 
TBAF as a reagent. Diene-alcohol 1.77 was formed in quantitative yield. Protecting alcohol 1.77 
with (-)-camphanoyl chloride 1.99 was achieved in the presence of triethylamine. The obtained 
camphanic ester 1.100 has a pair of diastereomers. Theoretically they are separable using silica 
gel column chromatography. Attempts to separate the diastereomers failed and proper solvent 
system cannot be found. Attempts to crystallize the diastereomers also failed to provide a single 
diastereomer. Successful separation would allow us to continue with the total synthesis with one 
enantiomer leaving the other behind. This mixture of diastereomers were used in the following 
epoxidation and dihydroxylation (Scheme 1.23). The epoxidation was performed as that similar 
to those described in section 1.3.5. Ester 1.100 was treated with MCPBA to obtain a mixture of 
isomers 1.101 and 1.102. This oxidation was not stereoselective. We tried to isolate this mixture, 
but couldn’t succeed. Final bid to separate these mixtures atleast in the dihydroxylation step; we 
took the mixture and subjected to dihydroxylation conditions as discussed earlier. A mixture of 
diols 1.103 was obtained. We could not separate the mixture of diols using a silica gel column 
chromatography. Change in protection group wasn’t assisting us for a better separation of 
diastereomers. This approach was not pursues further. 
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1.3.11 Using trifluoromethyldioxirane (TFDO) as a oxidizing agent to epoxidize diene 
1.63 
The oxidation of the diene 1.63 using MCPBA was not successful as discussed in section 
1.3.3; search for alternate methods of oxidation was carried out. An (S)-isomer of compound 
1.63 was reported by Fuchs45 where methyl(trifluoromethyl)dioxirane (TFDO)46 1.104 was used 
as an oxidizing agent to successfully oxidize the exo-double bond (Scheme 1.23).45 
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 Methyl(trifluoromethyl)dioxirane was used as an oxidizing agent to convert diene 1.63 to 
an epoxide. We obtained a mixture of epoxides, 1.62 and 1.106. The diene 1.63 was dissolved in 
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THF, acetonitrile and EDTA solution. Sodium bicarbonate was added followed by 1,1,1-
trifluoroacetone (CH3COCF3) and oxone (2KHSO5.KHSO4.K2SO4) in portions. 
Methyl(trifluoromethyl)dioxirane was generated in situ, which oxidizes the exo double bond to 
an epoxide. The reaction vessel was equipped with a dry ice condenser on the top and the 
reaction was carried out at 0 0C for 6 hrs. Workup was performed quickly followed by a flash 
silica gel column chromatography with 1% triethylamine as a co-solvent so as to avoid 
decomposition. After column chromatography 82% of desired mixture of epoxides 1.106 and 
1.62 were obtained along with 9% of starting material 1.63(recovered) (Scheme 1.25). The 
mixtures were not separable after column chromatography. A suitable solvent system was not 
found to separate them efficiently. On careful 1H, 13C NMR analysis, a mixture of isomers 1.106 
and 1.62 in 1:1 ratio was found. Signals for compounds 1.62 and 1.106 overlap except the 
hydrogens associated with C-OTBDMS show at δ 4.26 and 4.34 in proton NMR spectra. But the 
assignment of which signal to which compound was difficult. Also two sets of peaks were 
observed in 13C NMR spectrum. This clearly indicates the formation of two products 1.106 and 
1.62. 
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1.3.12 Dihydroxylation and separation of diastereomers 
The mixture of epoxides was taken and subjected to dihydroxylation conditions afforded 
diols 1.107 and 1.108. The same reaction conditions were carried out for dihydroxylation as 
discussed above.39 Dihydroxylation of a mixture of epoxides was performed using osmium 
tetraoxide (OsO4) in catalytic amounts, in the presence of N-methylmorpholine-N-oxide (NMO), 
tert-butanol and acetone-water as solvent system. Overnight stirring followed by careful 
evaporation of acetone and silica gel column chromatography of the brown crude product gave a 
mixture of two cis-diols 1.107 and 1.108 in 65% yield in 1:1 ratio (Scheme 1.26). The reduced 
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osmium is toxic in nature and a careful disposal of the waste was recommended. The separation 
of diols was difficult at this stage and it came as no surprise to us. We obtained the mixture of 
diols 1.107 and 1.108 in 1:1 ratio from the integration of proton NMR spectrum. 
Characterization of the side products even after column chromatography was not possible. 
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The separation of the diols was a difficult process even in this case. Earlier in section 
1.3.6, one of the major isomer was identified by treating the mixture of diols with TBDMSCl. 
Surprisingly only one TBDMS protected isomer turned out to be a crystal and was proven by X-
ray crystallography (Figure 1.4). Applying the same idea of protection of diols, Kaiyan took the 
mixture of the diols and treated with benzoyl chloride (C6H5COCl) instead of TBDMSCl. We 
were fortunate to get a better separation. Only one diol 1.108 reacted and the other 1.107 
remained unreacted. The benzoyl protected alcohol 1.109 was obtained in 43% yield and 
recovered diol 1.107 was obtained in 49% yield (Scheme 1.27). The reason for the reaction of 
diol 1.108 might be the alcohol at C2 in 1.108 is less hindered and easier to react. The 
unprotected diol 1.107 is structurally similar to compound 1.81 except change in the protecting 
group of alcohol at C4 position.  
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The NMR spectrum of compound 1.107 shows a multiplet at δ 3.99 for C6-H. The proton 
NMR spectrum was taken in a 200 MHz spectrometer. The peak at δ 3.99 appears as a multiplet 
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instead of a triplet of a doublet. Therefore the coupling constants were difficult to calculate. Both 
the signals for C5-H and C4-H appear at 3.82 as a multiplet. The two OH groups at C5 and C4 
appear as doublets at δ 2.45 and 2.32. Signals at δ 2.92 (doublet, J = 4.4 Hz) and δ 2.67 (doublet, 
J = 4.4 Hz) correspond to C2-hydrogens. 
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The proton NMR spectrum of compound 1.109 shows signals at δ 8.07, 7.58 and 7.49 for 
benzoyl group. Signal at δ 5.49 is assigned to C4-H and appears as a doublet with J value of 3 Hz 
which correspond to the coupling between C4-axial H with C5-equatorial H. The coupling 
constant of 3 Hz suggests an axial-equatorial coupling. The coupling constant of 3 Hz suggests 
that C4-H is oriented at the axial position. Signal at δ 4.13 is assigned to C6-H and appears as a 
triplet of a doublet with J values 11 Hz and 3.6 Hz respectively, which corresponds to the 
coupling between C6-equatorial H with C5-equatorial H (J = 11 Hz, equatorial-equatorial 
coupling), C7-equatorial H (J = 11 Hz, equatorial-equatorial coupling) and C7-axial H (J = 3.6 
Hz, equatorial-axial coupling). The intensities of the triplet of a doublet resonance in the 
spectrum show 1:1:2:2:1:1. The coupling constant of 11 Hz suggests that C6-H is in equatorial 
position. Signal at δ 3.98 is assigned to C5-H and appears as a multiplet because of coupling with 
C4-H, C6-H and hydrogen of C5-OH. Signals at δ 2.817 (doublet, J = 4.4 Hz) and δ 2.623 
(doublet, J = 4.4 Hz) correspond to C2-hydrogens.  
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(a) PhCOCl, Et3N, THF, 00C-r.t, 48hr  
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1.3.13 Synthesis of ketone 112 
Benzoyl diol 1.109 was methylated, followed by deprotection and oxidation is shown 
below in Scheme 1.28. The compound 1.109 was treated with trimethyloxonium 
tetrafluoroborate (Me3OBF4) in the presence of 1,8-bis(dimethylamino)naphthalene (proton 
sponge) as a base to yield methylated product 1.110 in 72% yield.  There was a little 
decomposition of the product observed during the course of the reaction. The epoxide underwent 
ring opening. Thus formed side products couldn’t be characterized. Methylated product 1.110 
was treated with potassium carbonate to cleave the benzoyl protected group to give back the 
alcohol 1.111. The cleavage was easy and quick to afford the alcohol 1.111 in 78% yield. The 
purification at each step of this long synthetic scheme was done by silica gel column 
chromatography. Many methods were reported for oxidation of alcohols. Swern oxidation was 
used earlier resulting the opening the epoxide and decomposition. So this procedure was 
discarded. Readily available o-iodoxybenzoic acid (IBX) was used to oxidize alcohols to ketones. 
This method successfully oxidized alcohols. Hence, alcohol 1.111 was oxidized to ketone 1.112 
in 94% yield (Scheme 1.28).  
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 Ketone 1.112 was not the preferred compound for the conversion to ovalicin because in 
the subsequent step, the addition of the side chain at C2, alkenyl lithium is not stereoselective. 
We obtained a mixture of isomers. The attack of alkenyl lithium was from both side’s cis and 
anti to methoxy group at C3. In order to obtain a single stereoisomer, we planned to invert the 
methoxy group at C3 so that it is cis to the existing OTBDMS group at C4. This kind of 
isomerization was reported by Corey on a different intermediate in this total synthesis of 
ovalicin.19 In Barton’s synthesis,20 compound 1.41 (Scheme 1.9) has the correct stereo and 
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regiochemistry to produce only one adduct 1.42. The methoxy group and silyl ether are cis 
allowing the addition reaction takes place from the opposite face. Thus giving only one adduct 
1.42, where the alkenyl lithium side chain was coming opposite to these groups. We followed 
Corey’s procedure by using potassium carbonate and methanol to invert the stereocenter at C5. 
Decomposition of the product was observed and the most probable reason could be the steric 
repulsion from the silyl ether group that prevent the deprotonation of C5 hydrogen (Scheme 
1.29).  
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1.3.14 Synthesis of ketone1.117and 1.118 
Diol 1.107 which was unreactive towards benzoylation in Scheme 1.27 was methylated 
and oxidized to obtain ketone 1.117. The diol 1.107 was methylated using trimethyloxonium 
tetrafluoroborate (Me3OBF4) and proton sponge as a base. This methylation gave three products. 
Two mono methylated compounds 1.114 and 1.115 in 1:1 ratio in 80% (combined) yield and one 
dimethylated product 1.116 in 15% yield (Scheme 1.30). The obtained ratio is 2.6:2.6:1 for 
compounds 1.114, 1.115 and 1.116 respectively. The separation of these methylated products 
was performed by silica gel column chromatography. The compounds were characterized using 
proton NMR and 13C NMR spectrum. The dimethoxy compound 1.116 showed two methoxy 
signals at δ 3.41 and 3.45, two CH-OMe peaks at δ 3.35 and 3.37 and CH-OSi signal at δ 4.03. 
Using proton NMR spectrum we can differentiate the two monomethoxy compounds as they 
differ in signals for C4 proton δ 4.0 and 3.95 for compounds 1.114 and 1.115 respectively. After 
the separation the compounds 1.114 and 1.115 were oxidized to corresponding ketones. The 
oxidation was carried out using IBX in DMSO to obtain ketones 1.117, 1.118 from alcohols 
1.114, 1.115 respectively in quantitative yields (Scheme 1.31). Monomethoxy compounds 1.114 
and 1.115 are differentiated even after oxidizing them to subsequent ketones. The two ketones 
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show distinct signals in proton NMR spectra. Compound 1.117 shows a doublet for C3 proton at 
δ 3.52 and multiplet for C4 proton at δ 4.19. Compound 1.118 shows a singlet for C2 proton at δ 
4.2 and a multiplet for C4 proton at δ 4.33. 
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1.3.15 Addition of alkenyll lithium reagent to ketone 1.112 
The preparation of alkenyl lithium reagent was discussed in section 1.3.8. The same 
procedure was carried in preparing and adding alkenyl lithium to the ketone 1.112. Ketone 1.112 
was dissolved in ether and small amount of toluene was added. This mixture was cooled to -78 
0C and the freshly prepared alkenyl lithium 1.11 was added to the ketone. This addition did not 
give a stereoselective addition, instead gave a mixture of isomers, 1.119 and 1.120 in 75% yield 
(Scheme 1.32). A computer generated chem3D model (shown below) may explain the lack of 
stereoselective addition to the ketone. The methoxy group at C3 is axial, offering some resistance 
to the attack of alkenyl lithium. Also the tert-butyl on TBDMS group offers some resistance to 
the alkenyl lithum attack. The alkenyl lithium addition to the ketone 1.112 is not seteroselective 
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giving a mixture of two compounds 1.119 and 1.120. If both the methoxy and OTBDMS groups 
are cis to each other and anti to the C-O bond of epoxide on C-1 then the addition is expected to 
be stereoselective resulting in one compound which should lead to ovalicin. The thus formed 
mixtures are not separable by silica gel column chromatography. We couldn’t find proper solvent 
to separate them efficiently. From proton NMR spectrum data we assume that the ratio of 1.119 
and 1.120 is 1:1. We assumed both the structures based on the methylene group protons of the 
spiroepoxide. One of the two compounds shows signal at δ 2.9 and 3.1 and the other shows 
signal at δ 2.38 and 2.39. It was difficult to assign which signal corresponds to which compound. 
The ambiguity still prevails. 
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1.3.16 Synthesis to ovalicin analogues 
All our attempts to separate the mixture of adducts 1.119 and 1.120 failed. Separation in 
the next step was another resort. First we tried to deprotect the silyl protecting group using 
TBAF. After column chromatographic separation only one compound was characterized and 
assumed to be 1.121. Further derivatization of this compound could help us to reveal the exact 
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stereochemistry and structure of the compound. The remaining fractions cannot be characterized 
using NMR spectrum, thus remained unidentified. Small amounts of starting material was 
recovered (Scheme 1.33). The other approach was to epoxidize the double bond which is allylic 
to alcohol at C2 position. Sharpless epoxidation procedure was used to oxidize the double bond. 
The only identificable product was assumed to be 1.122 (Scheme 1.34). Two dimensional NOE 
experiments must be performed to provide sufficient information to confirm the stereochemistry 
at C2 position.  
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1.3.17 Continuing study towards the total synthesis of ovalicin 
A lot of time has been invested in fixing the stereochemistry, isolation of isomers; using 
various protecting groups and different reagents, to synthesize an intermediate that leads to 
ovalicin. Although we got a structurally similar compound, an isomer of ovalicin but our goal 
wasn’t achieved. The major problem is making the methoxy position at C-3 and OTBDMS group 
at C-4 cis to each other in ketones 1.112 and 1.117. This can be achieved by converting 
compounds 1.109 and 1.107 to ketone 1.60. The on going experiments conducted by Huiping 
Zhao in our lab reveal that the total synthesis can be achieved only if the inversion is successful 
making both the C-3 methoxy and C-4 OTBDMS groups cis to each other and both of them are 
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trans to the C-O bond at C-1 position. Huiping added side chain to the other ketone 1.117. The 
addition produced an unwanted isomer 1.124 as a major product (Scheme 1.35). The 
stereochemical assignment was done based on the reported values.23 The proton NMR spectrum 
of compound 1.123 shows signals δ 5.48 and 5.1, whereas compound 1.124 shows signals at δ 
5.98 and 5.1 for alkenyl protons on the side chain.  
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 This result wasn’t encouraging. The only alternative to achieve the final compound was 
to change our strategy. This can be achieved several ways. The most easiest and convenient way 
to achieve this is to invert the stereochemistry at C3 position. Compound 1.109 was prepared 
form the method discussed in earlier sections. The benzoylated diol 1.109 should be inverted at 
C3 position. To achieve this, alcohol 1.109 at C3 position should be oxidized using IBX. Ketone 
1.125 will be reduced either using sodium borohydride or lithium selectride to obtain an alcohol 
1.126, cis to OTBDMS group. Further, methylation of 1.126 using Me3OBF4 should lead us to a 
methylated product 1.127. Deprotecting the benzoyl group should give us an alcohol 1.128 and 
oxidation of alcohol 1.128 to ketone 1.60 will be performed using IBX. The addition of side 
chain 1.11 to ketone 1.60 should afford only one adduct 1.59. Sharpless epoxidation followed by 
protection of TBDMS and oxidation of 1.130 will afford ovalicin (Scheme 1.36). This route to 
ovalicin should be effective and is carried by Huiping Zhao. 
 
 40
O
OCOPh
OH
OTBDMS
O
OCOPh
OTBDMS
O
O
OCOPh
OTBDMS
OH
c
O
OCOPh
OTBDMS
OMe
O
OH
OTBDMS
OMe
O
OTBDMS
OMe
O
O
OTBDMS
OMe
OH
O
OTBDMS
OMe
O
OH O
OH
OMe
O
OH
O
OMe
O
OH
O
(a) IBX, DMSO, 12 hr, r.t  (b) NaBH4 / Li Selectride  (c) Me3OBF4, proton sponge, CH2Cl2
(d) K2CO3, MeOH  (e) IBX, DMSO  (f) 11, Toluene  (g) VO(acac)2, t-BuOOH  (h) TBAF, THF
(i) IBX, DMSO
a b
d e f g
h
i
Ovalicin
Scheme 1.36
1.109
1.60 1.59
1.125 1.126 1.127
1.128
1.129 1.130
1 2
34
 
 
Diol 1.107 can also be converted to the desired ketone 1.60. A series of protection, 
functional group interconversions and deprotection will lead to desired ketone 1.60. Diol 1.107 
will be treated with acetyl chloride to protect both alcohols. Desilylation will be done using 
TBAF. Oxidation of 1.132 followed by selective reduction using lithium selectride should afford 
an alcohol 1.134. Protection of alcohol 1.134 using TBDMSCl followed by cleavage of acetyl 
groups should give us compound 1.136. Methylation of the diol 1.61 should give three 
compounds 1.136, 1.137 and 1.138. Oxidation of the compound 1.136 to 1.60 will be carried out 
using IBX (Scheme 1.37). The Ketone 1.60 is a vital intermediate to in the synthesis of ovalicin. 
The later steps to ovalicin are similar to the one in Scheme 1.36. The synthetic reaction described 
in the following scheme is carried by Huiping Zhao in our group. 
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1.4 Biological activity of ovalicin analogues 
During the synthesis of ovalicin we obtained a number of intermediates and a few of them 
were submitted to test the bioacivity. The tests were performed by Dr. Peter K. Chaing at 
University of California; SanFransisco. Detailed description of the experiments47, 48 is out of 
scope of this thesis. In order to evaluate the activity of these analogues, Luciferase assay tests 
were screened against T. brucei in vitro.47, 48  
Luciferase assay is used to measure the binding activity of transcription factor. Luciferase 
reporter vector is first introduced into the cells and then the cells are lysed. Lucifern is added to 
this extract along with magnesium and ATP.49 A catalytic oxidative carboxylation is observed 
when the enzyme and the substrates are combined. During this process light is emitted and is 
measured by luminometer. The light emitted is a direct measurement of the binding activity of 
the transcription factor.49 
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As we know that the TNP-470, a synthetic analogue of fumagillin inhibits the growth of 
Trypasonoma brucei, so the quest for synthetic analogues of structurally similar compounds is on 
its way. During our studies to the total synthesis, we discovered some novel compounds that 
inhibit the growth of T. brucei. The activity of these analogues was screened against T. brucei is 
summarized in the following table 1 (the results were provided by Dr. Peter Chiang). 
 
 
 
 
        Ovalicin Analogs 
 
       IC50 (μg/mL) 
      1 
SB-5-87-
F4-6 
O
OH
OMe
OTBDMS
O
OH
OMe
OTBDMS
 
 
         0.16 ± 0.02    
 
2 
KL-1-71 
                      
O
OH
OH
OCOPh  
 
          0.19 ± 0.04 
             
 
3 
SB-3-15-F7 
                      
O
OH
OMe
OCOPh  
 
 
         1.64 ± 0.19    
 
4 
KL-2-26 
                     
O
OCOPh
O
OMe
 
 
 
         13.06             
 
5 
Ovalicin 2 
                     
O
OH
OH
OCamp  
 
         110.61 
             
 
Table 1.1 IC50 values of different intermediates screened against T.brucei. 
 
From the above table it is clearly evident that the compounds in entry 1 (SB-5-87-F4-6) is 
the most potent drug and compound in entry 2 (KL-1-71) is the next with IC50 values of 160 
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ng/mL and 190 ng/mL respectively. Especially compound in entry 2 which was synthesized in 6 
steps can serve as a lead compound to inhibit T.brucei. Compound in entry 3 (SB-3-15-F7) also 
inhibits the growth of T.brucei but less compared to compounds in entries 1 and 2. The 
compounds in entries 4 (KL-2-26) and 5 (ovalicin 2) are less active. 
 The antiparasitic activity of the two potent drugs, compounds in entries 1 and 2 is shown 
in the following figures 1.6 and 1.7 respectively. Both compounds inhibit the T.brucei growth 
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             Figure 1.6 Antiparasitic activity of analogue SB-5-87-F4-6 
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             Figure 1.7 Antiparasitic activity of analogue KL-1-71 
 
 TNP 470 is a synthetic drug which is currently in clinical trials has some issues like short 
physiological half-life and severe side effects, so our compounds should be promising candidates 
and can best serve as agents to inhibit the growth of these parasites.  
 
1.5 Experimental section 
General Methods. Nuclear Magnetic Resonance (NMR) spectra were recorded on a 400 
MHz and 100 MHz Varian spectrometer in CDCl3 unless otherwise specified. The chemical 
shifts are given in parts per million (ppm) from downfield from tetramethylsilane as internal 
standard. Coupling constants (J) are given in hertz. TLC analyses were performed on thin-
layer analytical plates from Aldrich. All the reactions were performed in argon atmosphere 
unless otherwise specified. Silical gel (200~400 mesh) from Natland corporation was used 
for column chromatographic separations. Solvents like THF and diethyl ether were distilled 
over sodium and benzopheneone, methylene chloride was distilled over CaH2 and finally 
benzene and toluene were distilled over LiAlH4.  
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Ethyl (Z)-β-Iodoacrylate (1.67)30, 31 (SB-3-45)  
                                                             I COOEt  
 
To a round bottom flask, 12.8 g (0.085 mol) of sodium iodide and 50 mL of glacial acetic 
acid was added. Then 8.37 g (0.085 mol) of ethyl propiolate was added to the above mixture. 
The resulting mixture was heated to 70 0C for 12 hours. The resultant yellow solution was 
washed with 3 M NaOH and extracted with diethyl ether. The organic layer was washed with 
brine and dried over anhydrous sodium sulfate, filtered and concentrated. Distillation was 
performed under reduced pressure to obtain pure 17.2 g (89.2% yield) of 1.67. 1H NMR 
(CDCl3): δ 7.44 (d, J = 9 Hz, 1 H, =CH), 6.89 (d, J = 8 Hz, 1 H, =CHCOOEt), 4.25 (q, J = 7 
Hz, 2 H, OCH2), 1.32 (t, J = 8 Hz, 3 H, CH3); 13CNMR: δ 164.7 (C=O), 130.2, 94.5, 60.9, 
14.3. 
 
(Z)-β-iodoacrolein (1.65)30, 31 (SB-3-43) 
                                                                    I CHO  
 
A solution of 3.74 g (0.017 mol) of iodoacrylate 1.67 in 40 mL of freshly distilled CH2Cl2 
was cooled to – 78 0C. To this solution 1 M DIBAL-H in toluene was added dropwise via 
syringe and stirred at -78 0C for one hour. The reaction was monitored by TLC using hexane 
and diethyl ether as solvent. The resultant solution was not allowed to warm to room 
temperature because of fear of conversion to (E)-siomer. The formation of aldehyde was 
confirmed by taking a 1H NMR. So no work up was performed and this aldehyde 1.65 was 
directly used in the next step. On long standing this compound will isomerizes to form a 
trans aldehyde. 1H NMR (CDCl3): δ 9.5 (d, J = 6 Hz, 1 H, CHO), 8.0 (d, J = 8 Hz, 1 H, =CH), 
7.2 (dd, J = 8 Hz, J = 6 Hz, 1 H, =CHCHO). 
 
(Z)-1-Iodohepta-1,6-dien-3-ol (1.68) (SB-3-44) 
                                                           I OH
1
2
3
4
5
6
7  
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A three neck 200 mL round bottom equipped with a dropping funnel and a water condenser 
was charged with 1.58 g (0.067 mol) of magnesium turnings and 30 mL THF under argon. 
This mixture was stirred vigorously and heated to reflux at 70 0C. 4-Bromo-1-butene was 
added to this heated mixture drop wise via dropping funnel. Then this whole mixture was 
heated to reflux for 2 hours. This reaction mixture was cooled to room temperature to give 
alkenyl magnesium bromide, a Grignard reagent. This mixture was kept under argon. 
Without any further delay this freshly prepared Grignard solution was added to aldehyde 1.65 
slowly via cannula at -78 0C. This solution was stirred at -78 0C for one hour and then slowly 
warmed to room temperature. The resulting solution was diluted with water and extracted 
with diethyl ether. The organic layer was washed with saturated solution of NaHCO3 and 
brine, dried over anhydrous sodium sulfate, filtered and concentrated. Column 
chromatographic separation on silica gel using hexane and diethyl ether (1:1 v/v) afforded 
2.95 g (74% yield) of a colorless liquid. 1H NMR (CDCl3) δ 6.35 (d, J = 8 Hz, 1 H, C1-H), 
6.27 (t, J = 8 Hz, 1 H, C2-H), 5.86 (m, 1 H, C6-H), 4.9 (dd, 1 H, C7-H ), 5.1 (dd, 1 H, C7-H), 
4.4 (q, J = 8 Hz, 1 H, C3-H), 2.2 ( m, 2 H, C5-H), 1.65 (m, 2 H, C4-H); 13C NMR 143.4, 
138.2, 115.4, 82.7, 74.2, 35.1, 29.5. 
 
(Z)-1-Iodo-3-(tert-butyldimethylsilyloxy)-1,6-heptadiene (1.69) (SB-3-57) 
                                          
                                               I OTBDMS
1
2
3
4
5
6
7  
 
A solution of 5.6 g (0.023 mol) of alcohol 1.68 and distilled DMF, 40 mL was stirred at 0 0C. 
Then to this solution 4.8 g (0.071 mol) of imidazole was added. Catalytic amount of 4-
dimehtylaminopyridine (DMAP) (2 g) was added to the above mixture. This mixture was stirred 
for 10 min at 0 0C. To this mixture 4.61 g (0.031 mol) of tert-butyldimethylsilyl chloride 
(TBDMSCl) was added. Slowly the reaction mixture was warmed to room temperature and 
stirred overnight. The progress of the reaction was monitored by TLC using hexane and diethyl 
ether (50:1 v/v) as a developing solvent. The resulting solution was diluted with water and 
extracted with diethyl ether. The organic layer was washed with 1H HCl, aqueous NaHCO3 and 
brine. The organic extract was dried over anhydrous sodium sulfate and concentrated to dryness. 
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Column chromatographic separation on silica gel using mixture of hexane and diethyl ether (50:1 
v/v) afforded 8.114 g (98% yield) of title compound 1.69. 1H NMR (CDCl3) δ 6.19 (s, 2 H, HC-
1=C-2H), 5.85 (m, 1 H, C6-H), 5.03 (d, J = 1 Hz, I H, =C-7H), 4.9 (d, J = 10 Hz, 1 H, =C-7H), 
4.3 (q, J = 6 Hz, 1 H, C3-H), 2.08 (m, 2 H, C-5H2), 1.67 (m, 2 H, C-4H2), 0.88 (s, 9 H, t-Bu), 
0.09 (s, 3 H, SiCH3), 0.05 (s, 3 H, SiCH3): 13C NMR δ 144.8, 138.6, 114.9, 80.07, 75.2, 36.21, 
29.4, 26.06, 18.3, -3.98. 
 
3-Methylene-6-(tert-butyldimethylsilyloxy)cyclohexene (1.63) (SB-3-58) 
                                                             OTBDMS
1
2
3
4
5
6
7
 
A round bottom flask was charged with 0.52 g (2.3 mmole) of palladium acetate (II), 9.7 g 
(0.023 mole) of silver phosphate and 1.21 g (4.6 mmol) of triphenyl phosphene. The flask was 
vaccum and flame dried and kept under argon. Then 10.8 g (0.051 mol) of proton sponge was 
added to the round bottom and the resulting mixture was kept under argon. Then 100 mL of 
distilled DMF was added to the reaction mixture and the resulting solution was heated to 70 0C 
for 12 hours. This mixture was filtered through a pad of celite 545, diluted with water and 
extracted with diethyl ether. The organic layer was washed with 1 M HCl, aqueous sodium 
bicarbonate and brine. Organic layer was dried over anhydrous sodium sulfate and concentrated 
to dryness. Column chromatographic separation on silica gel using a gradient mixture of hexane 
and diethyl ether (50:1 v/v) afforded 4.81 g (93% yield) of 1.63.1H NMR (CDCl3) δ 6.1 (d, J = 
10 Hz, 1 H, C-2H), 5.7 (d, J = 10 Hz, 1 H, C-1H), 4.8 (d, J = 5 Hz, 2 H, C-7H2), 4.3 (q, 1 H, C-
6H), 2.4 (m, 1 H, C-4H), 2.22 (m, 1 H, C-4H), 1.9 (m, 1 H, C-5H), 1.63 (m, 1 H, C-5H), 0.9 (s, 9 
H, t-Bu), 0.09 (s, 3 H, SiCH3), 0.09 (s, 3 H, SiCH3) 13C NMR δ 142.6, 133.9, 130.2, 111.9, 67.1, 
32.9, 27.9, 26.1, 18.4, -4.34, -4.39. 
 
3-Methylene-6-(hydroxy)cyclohexene (1.77) (SB-2-38) 
OH  
 48
To a solution of 1.3 g (5.8049 mmol) of 1.63 in 20 mL of distilled THF was added 4.2 mL of 
TBAF (1 M in THF) at 0 0C. The reaction mixture was stirred at 0 0C for 10 hours. The resulting 
solution was washed with water. The organic layer was washed with brine and extracted with 
ethyl acetate, dried over anhydrous sodium sulfate and concentrated to dryness. The resulting 
solution was not purified by column chromatography and directly used for next reaction. 1H 
NMR (CDCl3) δ 6.209 (d, J = 9 Hz, 1 H, =CH), 5.808 (d, J = 10 Hz, 1 H, =CH), 4.878 (s, 2 H, 
CH2), 4.33 (m, 1 H, CHOH), 2.6-2.2 (m, 2 H, CH2), 2.1-1.6 (m, 2 H, CH2); 13C NMR (CDCl3) δ 
142.1, 132.2, 131.4, 112.9, 66.1, 32.4, 27.3. 
 
3-Methylene-6-(benzoyloxy)cyclohexene (1.78) (SB-2-39) 
      OCOPh
1
2
3
4
5
6
7
 
To a 5.81 mmol of alcohol 1.77, 4.8 mL (34.8 mmol) of distilled triethylamine was added and 
stirred at 0 0C for 10 minutes. Then 2.6 mL (14.51 mmol) of benzoyl chloride was added and 
stirred at 0 0C. The resulting solution was slowly allowed to warm to room temperature. Then the 
reaction was stirred at room temperature for 6 hours. The progress of the reaction was monitored 
by TLC using hexane and diethyl ether (3:1 v/v) as a developing solvent. The resulting solution 
was washed with water and extracted with ether. The organic layer was washed with 1 M HCl, 
aqueous sodium bicarbonate and brine. The organic layer was dried over anhydrous sodium 
sulfate, concentrated and applied to column chromatography (silica gel) using gradient mixture 
of hexane and diethyl ether (3:1 v/v) afforded 1.09 g (88%) of 1.78. 1H NMR (CDCl3) δ 8.1 (m, 
2 H, Ar), 7.5 (m, 1 H, Ar), 7.4 (m, 2 H, Ar), 6.31 (d, J = 9 Hz, 1 H, C2-H), 5.9 (dd, J = 4 Hz, J = 
4 Hz, 1 H, C1-H), 5.6 (m, 1 H, C6-H), 4.95 (s, 2 H, C7-H), 2.6 (m, 1 H, C4-H), 2.4 (m, 1 H, C4-
H), 2.16 (m, 1 H, C5-H), 1.97(m, 1 H, C5-H). 13C NMR δ 166.3, 141.5, 133.3, 133.0, 129.7, 
128.4, 127.5, 113.9, 68.7, 28.5, 26.9. 
 
(3R*,8R*) and (3R*,8S*)-6-(Benzoyloxy)-1-oxaspiro[2.5] oct-4-ene (1.79 & 1.80) (SB-
2-47) 
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O
OBz
O
OBz
1.79 1.80
12
3 4
56
 
 
To a solution of 1 g (4.673 mmol) of diene 1.78 in 25 mL of methylene chloride was added 334 
mg (7.944 mmol) of sodium fluoride and 190 mg (3.27 mmol) of potassium fluoride. The 
reaction vessel was cooled to 0 0C. Then 1.21 g (7.01 mmol) of meta-chloroperbenzoic acid 
(MCPBA) was added to the reaction mixture. This mixture was stirred at 0 0C for 5 hours. Using 
TLC (hexane, diethyl ether (9:1)) the reaction progress was monitored. The resulting mixture 
was washed with water and extracted with diethyl ether. The organic layer was washed with 
aqueous sodium thiosulfate, aqueous sodium bicarbonate and brine. The organic layer was dried 
over anhydrous sodium sulfate and concentrated to dryness under vacuum. Without further 
purification the residue was dihydroxylation in the next step. We did not observe any starting 
material diene 1.78 in the crude proton NMR, so we assumed a complete conversion. We 
obtained a mixture of two compounds 1.79 and 1.80 in 1:1 ratio (based on integration in proton 
NMR). The assignments either to the proton signals or 13C signals are based on our assumptions. 
It was difficult to assign a set of signals to its respective compound. 1H NMR (CDCl3) δ (for one 
compound) 8.062 (m, 2 H, CH of Ph), 7.569 (m, 1 H, CH of Ph), 7.447 (m, 2 H, CH of Ph), 
6.184 (dd, J = 3 Hz, J = 4 Hz, 1 H, =CH), 5.632 (m, 1 H, CHOCOPh), 5.498 (t, J = 10 Hz, 1 H, 
=CH), 2.895 (d, J = 5 Hz, 1 H, CHO), 2.875 (d, J = 2 Hz, 1 H, CHO), 2.86-2.96 (m, 2 H, CH2), 
1.83-2.34 (m, 2 H, CH2); 1H NMR (CDCl3) δ (for another compound) 8.06 (m, 2 H, CH of Ph), 
7.573 (m, 1 H, CH of Ph), 7.452 (m, 2 H, CH of Ph), 6.159 (dd, J = 3 Hz, J = 4 Hz, =CH), 5.598 
(m, 1 H, CHOCOPh), 5.495 (t, J = 10 Hz, 1 H, =CH), 2.952 (d, J = 5 Hz, 1 H, CHO), 2.863 (d, J 
= 2 Hz, 1 H, CHO), 2.86-2.96 (m, 2 H, CH2), 1.83-2.34 (m, 2 H, CH2); 13C NMR (CDCl3) (for 
one compound) δ 166.3, 133.6, 133.3, 133.3, 130.5, 129.9, 128.6, 68.3, 55.2, 55.1, 27.4, 27.3; 
13C NMR (CDCl3) (for another compound) δ 166.2, 133.2, 133.0, 132.8, 130.4, 129.8, 128.6, 
67.7, 55.2, 55.1, 27.3, 27.1. 
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(3S*,4S*,5R*,6R*)-6-(Benzoyloxy)-1-oxaspiro[2.5]octane-4,5-diol (1.82), (3S*,4R*,5S*,6S*)-
6-(benzoyloxy)-1-oxaspiro[2.5]octane-4,5-diol (1.81) & (3S*,4R*,5S*,6R*)-6-(benzoyloxy)-
1-oxaspiro[2.5]octane-4,5-diol (1.83) (SB-2-48) 
O
OBz
O
OBz
OH
OH
O
OBz
OH
OH
OH
OH
1.81 1.82 1.83  
To a solution of 1g (4.3478 mmol) of mixture of epoxides (1.79 and 1.80) in 32 mL of acetone 
and water (3:1) and 5 mL of t-butanol was added 1.528 g of NMO and 221 mg of OsO4. The 
reaction was stirred at room temperature for 30 hours. The resulting solution was extracted with 
ether and washed with water and brine. The water layer was washed with ether three times. The 
organic layers were dried on anhydrous sodium sulfate and concentrated to dryness. The 
resulting residue was purified by column chromatography using a mixture of hexane and ethyl 
acetate (1:1 v/v). After column we obtained 0.526 g (46%) of mixture of diols in 5:4:1 ratio. It 
was difficult to identify the other fractions by NMR. Herein we assumed that the mixture of diols 
consists of three diastereomers mainly. The isomers were identified based on the splitting pattern 
and J coupling values by Kaiyan. Later Kaiyan silylated this mixture of diols, only one 
crystalline product 1.84 was obtained and isolated. On desilylation compound 1.81 was obtained 
and characterized by NMR. 1H NMR (CDCl3) (for compound 1.81) δ 8.06 (m, 2 H, Ph), 7.59 (m, 
1 H, Ph), 7.46 (m, 2 H, Ph), 5.35 (td, J = 8 Hz, 2 Ha-Ha, J = 4 Hz, Ha-He, 1 H, CH-OCOPh), 
4.11 (m, 1 H, CHOH), 3.73 (s, 1 H, CHOH), 3.21 (d, J = 4 Hz, 1 H, CHO), 3.05 (d, J = 2 Hz, 
CHO), 2.22- 2.0 (m, 2 H, CH2), 1.9- 1.6 (m, 2 H, CH2); 13C NMR (CDCl3) (for compound 1.81) 
δ 166.6, 133.3, 129.8, 129.7, 128.4, 73.0, 72.6, 72.8, 58.7, 51.7, 26.0, 25.7; 1H NMR (CDCl3) 
(for compound 1.82) δ 8.05 (m, 2 H, Ph), 7.59 (m, 1 H, Ph), 7.46 (m, 2 H, Ph), 5.41 (td, J = 7.2 
Hz, 2 Ha- Ha, J = 4 Hz, Ha-He 1 H, CH-OCOPh), 4.00 (m, 1 H, CHOH), 3.86 (dd, J = 6 Hz, J = 
3 Hz, 1 H, CHOH), 2.91 (d, J = 5 Hz, 1 H, CHO), 2.65 (d, J = 5 Hz, 1 H, CHO), 2.3-1.7 (m, 4 H, 
2 CH2); 1H NMR (CDCl3) (for compound 1.83) δ 8.07 (m, 2 H, Ph), 7.58 (m, 1 H, Ph), 7.46 (m, 
2 H, Ph), 5.18 (dt, J = 10 Hz, He-He, J = 3 Hz, 2 Ha-He, 1 H, CH-OCOPh), 4.35 (bs, 1 H, 
CHOH), 3.81 (d, J = 2.5 Hz, 1 H, CHOH), 3.07 (d, J = 5 Hz, 1 H, CHO), 2.71 (d, J = 4.8 Hz, 1 H, 
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CHO), 2.22-1.60 (m, 4 H, 2 CH2); 13C NMR (CDCl3) (for compound 1.83) δ 166.3, 133.5, 130.3, 
130.0, 128.7, 72.9, 71.3, 71.1, 58.9, 51.1, 26.7, 24.7. 
 
 
(3S*,4R*,5S*,6S*)-6-(Benzoyloyz)-5-methoxy-1-oxaspiro[2.5]octan -4-o1 (1.85) & 
(3S*,4R*,5S*,6S*)-6-(benzoyloxy)-4-methoxy-1-oxaspiro[2.5]octan -5-o1 (1.86) (LK-2-24) 
O
OBz
OH
OMe
O
OBz
OMe
OH
1.851.86  
To a solution of 194 mg (0.733 mmol) of compound 1.81 in 3 mL of methylene chloride, 314 mg 
(1.465 mmol) of 1,8-bis(dimethylamino)naphthalene (proton sponge) and 108 mg (0.732 mmol) 
of trimethyloxonium tetrafluoroborate was added. The reaction vessel was cooled to 0 0C. The 
reaction was stirred at 0 0C for nine hours. The resultant solution was washed with water and 
extracted using ether. The organic layer was washed with 1 M HCl, aqueous sodium bicarbonate 
and brine. The organic layer was dried over anhydrous sodium sulfate and concentrated to 
dryness. The residue was applied to column chromatography for separation using hexane and 
ethyl acetate (3:2 v/v). Obtained mixture of compounds 1.86 and 1.85 in 1:1.3 ratio. The ratio of 
compounds was calculated based on the column chromatographic separation. This experiment 
was taken from Kaiyan with his permission. 1H NMR (CDCl3) (for compound 1.86) δ 8.07 (m, 2 
H, Ph), 7.56 (m, 1 H, Ph), 7.45 (m, 2 H, Ph), 5.32 (m, 1 H, CH-OCOPh), 3.99 (dt, J = 3.2 Hz, J = 
8 Hz, 1 H, CHOH), 3.46 (s, 3 H, OMe), 3.18 (d, J = 3 Hz, 1 H, CHOMe), 2.93 (d, J = 5 Hz, 1 H, 
CHO), 2.81 (d, J = 5 Hz, 1 H, CHO), 2.51 (d, J = 4 Hz, 1 H, OH) 2.56-1.36 (m, 4 H, 2 CH2); 13C 
NMR (CDCl3) (for compound 1.86) δ 166.6, 133.2, 130.0, 129.4, 128.6, 83.0, 73.3, 72.8, 58.4, 
57.2, 52.7, 26.3, 26.2; 1H NMR (CDCl3) (for compound 1.85) δ 8.06 (m, 2 H, Ph), 7.59 (m, 1 H, 
Ph), 7.47 (m, 2 H, Ph), 5.43 (dt, J = 9 Hz, J = 4 Hz, J = 8 Hz, 1 H, CH-OCOPH), 3.66 (t, J = 3.2 
Hz, J = 7.6 Hz, 1 H, CHOMe), 3.49 (s, 3 H, OMe), 2.93 (d, J = 5 Hz, 1 H, CHO), 2.76 (d, J = 5 
Hz, 1 H, CHO), 2.51 (d, J = 3 Hz, 1 H, OH), 2.17-1.52 (m, 4 H, 2 CH2); 13C NMR (CDCl3) (for 
compound 1.85) δ 166.0, 133.2, 129.9, 129.8, 128.6, 81.8, 71.3, 71.3, 58.8, 58.7, 51.9, 26.1, 26.1. 
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(3S*,5R*,6S*)-6-(benzoyloxy)-5-methoxy-1-oxaspiro[2.5]octan-4-one (1.87) (SB-2-67) 
      
O
O
OMe
OCOPh
12
3
4
56
 
 
To a solution of 16 mg (0.058 mmol) of alcohol 1.85 in 2 mL of methylene chloride was added 
73.14 mg (0.1725 mmol) of Dess Martin periodinane at 0 0C. The reaction mixture was allowed 
to reach room temperature and allowed stirred for 2 hours. The reaction mixture was washed 
with aqueous sodium thiosulfate and extracted using diethyl ether. The organic layer was washed 
with aqueous sodium bicarbonate and brine, dried over anhydrous sodium sulfate, filtered and 
concentrated. Column chromatographic separation on silica gel using hexane and ethyl acetate as 
eluent (1:1 v/v) afforded 6 mg (38% yield) of title compound 1.87. 1H NMR (CDCl3) δ 7.99 (d, J 
= 8 Hz, 2 H, Ph), 7.58 (t, J = 7 Hz 1 H, Ph), 7.45 (t, J = 8 Hz, 2 H, Ph), 5.5 (q, 1 H, C-6H), 3.88 
(d, J = 5Hz, 1 H, C-5 HOMe), 3.41 (s, 3 H, OMe), 3.01 (d, 1 H, J = 6 Hz, OCH2), 2.9 (d, 1 H,  J 
= 6 Hz, OCH2), 2.4 (m, 2 H, CH2), 2.2 (m, 2 H, CH2); 13C NMR (CDCl3) δ 203, 165, 137, 133.5, 
129.7, 128.6, 83.9, 72.7, 59.0,54.04, 29.9, 27.3, 24.4.  
 
2,4,6-Triisopropylbenzenesulphonyl chloride (1.7)26, 27 (SB-2-53) 
      
SO2Cl
 
 
A round bottom flask was charged with 5 g (0.025 mol) of 1,3,5-triisopropyl benzene and 
dissolved in 25 mL of CH2Cl2. This vessel was cooled to 0 0C and 7.16 mL (0.1078 mol) 
chlorosulfonic acid (ClSO3H) was added dropwise to the above solution. This solution was 
stirred at 0 0C for 1 hour. The resultant solution was poured into crushed ice and washed with 
water and extracted with CH2Cl2. The organic layer was washed with brine and dried over 
anhydrous sodium sulfate. Column chromatographic separation on silica gel using mixture of 
hexane and diethyl ether (1:1 v/v) afforded 7.29 g (98% yield) of 1.7. 1H NMR (CDCl3) δ 7.26 (s, 
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2 H, Ar), 4.23 (hept, 2 H, CH), 2.93(hept, 1 H, CH), 1.31 (d, J = 7 Hz, 12 H, CH3), 1.27 (d, J = 7 
Hz, 6 H, CH3); 13C NMR (CDCl3) δ 155.8, 150.56, 139.44, 124.5, 34.57, 29.9, 24.56, 23.64. 
 
2,4,6-Triisopropylbenzenesulphonyl hydrazine (1.8)26, 27 (SB-2-54) 
      
SO2NHNH2
 
A round bottom flask was charged with 7.29 g (0.0241 mol) of 1.7 and was dissolved in 10 mL 
of THF. The resulting solution was cooled to 0 0C and 2.17 mL (0.0602 mol) of hydrazine was 
added and stirred at 0 0C for 4 hours. The resultant solution was washed with water and extracted 
with diethyl ether three times. The organic layer was washed with brine and dried over 
anhydrous sodium sulfate and concentrated to give 6 g (83 % yield) of title compound 1.8. 1H 
NMR (CDCl3) δ 7.23 (s, 2 H, Ar), 5.4 (bs, 3 H, NH), 4.15 (hept, 2 H, CH), 2.76 ( hept, 1 H, CH3), 
1.28 (d, J = 5 Hz, 12 H, CH3), 1.26 (d, J = 5 Hz, 6 H, CH3); 13C NMR (CDCl3) δ 151.99, 141.5, 
124.2, 34.4, 29.96, 25.1, 23.7 
 
2,4,6-Triisopropylbenzenesulphonyl hydrazone (1.9)26, 27 (SB-2-117) 
     
SO2NHNC(CH3)2
 
To compound 1 g (3.305 mmol) of 1.8 was dissolved in 15 mL of distilled acetone. The reaction 
was stirred at room temperature for half an hour. The excess acetone was pumped off using a 
rotavapour. The 5 mL of CH2Cl2 and 5 mL of toluene was added to the above solution and 
pumped off using a rotavapor. Then the resultant light yellow solid was dried over P2O5 in a 
desiccator under high vaccum for one day to get rid of any moisture or traces of water. Obtained 
1.0 g (91% yield) of 1.9. 1H NMR (CDCl3) δ 7.16 (s, 2 H, Ar), 7.08 (bs, 1 H, NH), 4.2 (hept, 2 H, 
CH), 2.76 (hept, 1 H, CH), 1.9 (s, 3 H, CH3), 1.78 (s, 3 H, CH3), 1.28 (d, J = 5 Hz, 12 H, CH3), 
1.26 (d, J = 5 Hz, 6 H, CH3); 13C NMR (CDCl3) δ 153.3, 151.5, 123.97, 34.35, 30.12, 24.98, 
23.75, 16.59. 
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Preparation of akenyl lithium (1.11)19, 26, 27 (SB-2-118) 
      Li  
 
A round bottom flask was charged with 350 mg (1.036 mmol) of 1.9 in freshly distilled 4 mL of 
DME. This resulting solution was stirred and cooled to -78 0C. Then 2.15 equivalents (1.4 mL) 
of n-BuLi was added to the above solution, the solution turns to yellow color. The resulting 
solution was monitored very carefully and slowly warmed to -66 0C over 20 minutes and again 
recooled to -78 0C. To this solution 0.143 mL (1.243 mmol) of 1-Bromo-3-methyl-2-butene was 
added at -78 0C. The solution was warmed to -66 0C over 20 minutes and allowed to stir at -66 
0C for one hour and again recooled to -78 0C. Then a chelating base TMEDA (0.52 mL 3.42 
mmol) was added and 0.712 mL (1.139 mmol) of n-BuLi was added. The above solution was 
allowed to warm to -3 0C over 2 hours and recooled to -78 0C. Assuming 100% conversion to 
alkenyl lithium, this solution was added to ketone 1.87. 
 
(3S*,4S*,5R*,6S*)-4-(1’,5’-Dimethylhexa-1’,4’-dienyl)-5-methoxy-6-benzoyloxy-1-
oxaspiro[2.5]octan-4-ol (1.92) and (3S*,4S*,5R*,6S*)-4-(1’,5’-Dimethylhexa-1’,4’-dienyl)-5-
methoxy-6-hydroxy-1-oxaspiro[2.5]octan-4-ol (1.93) (SB-3-15) 
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To a solution of 49 mg (0.1775 mmol) ketone 1.87 in 0.5 mL diethyl ether and 0.5 mL of toluene 
two equivalents of alkenyl lithium 1.11 was added at -78 0C. The resulting solution was stirred 
for one hour at -78 0C and slowly allowed to reach room temperature. The progress of the 
reaction was monitored by TLC using hexane and diethyl ether (2:1 v/v) as a developing solvent. 
Then the reaction was quenched with aqueous ammonium chloride and extracted with CH2Cl2. 
The organic layer was washed with brine, dried over anhydrous sodium sulfate, filtered and 
concentrated to dryness under vaccum. Column chromatographic separation on silica gel using 
gradient mixture of hexane and ethyl acetate (1:1 v/v) afforded 10 mg of 1.92 (15%) and 5 mg of 
 55
1.93 (10%).It was difficult to characterize the remaining fractions. The stereoisomer at C4 of 
compound 1.93 was not identified. The stereochemistry of both the structures was confirmed 
based on the derivatization in the later steps. 1H NMR (1.92) (CDCl3) δ 8.08 (d, J = 9 Hz, 2 H, 
Ar), 7.59 (t, J = 4 Hz, 1 H, Ar), 7.562 (t, J = 2 Hz, 2 H, Ar), 6.13 (t, J = 7 Hz, 1 H, =CH), 5.58 (m, 
1 H, CHOCOPh), 5.14 (t, J = 5 Hz, 1 H, =CH), 3.6 (s, 3 H, OMe), 3.56 (m, 1 H, CHOMe), 3.3 (d, 
J = 5 Hz, 1 H, CHO), 2.82 (d, J = 5 Hz, 1 H, CHO), 2.78 (m, 2 H, CH2), 1.714 (s, 3 H, CH3), 
1.712 (s, 3 H, CH3), 1.65 (s, 3 H, CH3). 1H NMR (1.93) (CDCl3) δ 5.90 (doublet of a triplet , J = 
4 Hz, J = 1 Hz, 1 H, =CH), 5.11 (m, 1 H, HC=), 3.89 (m, 1 H, CHO), 3.68 (s, 3 H, OMe), 3.13 (d, 
J = 8 Hz, 1 H, CHO), 2.74 (d, J = 6 Hz, 1 H, CHO), 2.01 (m, 2 H, CH2), 1.72 (s, 3 H, CH3), 1.69 
(s, 3 H, CH3), 1.63 (s, 3 H, CH3), 1.5 (m, 2 H, CH2). 
 
(3S*,4S*,5R*,6S*)-4-(1’,5’-Dimethylhexa-1’,4’-dienyl)-5-methoxy-6-oxo-1-
oxaspiro[2.5]octan-4-ol (1.94) (SB-3-33) 
     
O
OH
OMe
O  
 
A round bottom was charged with 7 mg (0.0247 mmol) of 1.93 and 1 mL DMSO at room 
temperature. To the above mixture 14 mg (0.0495 mmol) of IBX was added and stirred at room 
temperature for 5 hours. The reaction mixture was washed with water and extracted with diethyl 
ether. The organic layer was washed with brine and dried over anhydrous sodium sulfate, 
concentrated and applied to column chromatography (silica gel). Hexane and diethyl ether (1:1 
v/v) was used as an eluent to afford 4 mg (58% yield) of title compound 1.94. The 
stereochemistry of 1.94 was confirmed based on the derivatization in the later step. 1H NMR 
(CDCl3) δ 5.76 (t, J = 8 Hz, 1 H, =CH), 5.02 (t, J = 5 Hz, 1 H, =CH), 4.01 (s, 1 H, CHOMe), 
3.58 (s, 3 H, OMe), 3.43 (d, J = 5 Hz, 1 H, CH2O), 2.91 (d, J = 5 Hz, 1 H, CH2O), 2.706 (m, 2 H, 
CH2), 2.19 (m, J = 5 Hz, 2 H, CH2), 1.67 (s, 3 H, CH3), 1.63 (s, 3 H, CH3), 1.59 (s, 3 H, CH3), 
1.45 (dd, J = 5 Hz, 2 H, CH2). 
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(3S*,4S*,5R*,6S*)-4-(2’-Methyl-3’-(3’’-methylbut-2’’-enyl)oxiran-2’-yl)-5-methoxy-6-oxo-
1-oxaspiro[2.5]octan-4-ol (1.95) (SB-3-37) 
     
O
OH
OMe
12
3
4
56
7
8
O
O
 
To a solution of 3.5 mg (0.0125 mmol) of ketone 1.94 and 0.5 mL of toluene, 0.019 M in toluene 
of vanadyl acetoacetonate (0.0025 mmol) was added at 0 0C. Then 0.1 M in toluene (0.04 mmol) 
of tert-butylhydroperoxide was added to the above mixture. After 3 hours stirring at 0 0C there 
was a new spot on TLC. Without any workup the reaction mixture was loaded on to a silica gel 
column chromatography using hexane and ethyl acetate (1:1 v/v) as an eluent to yield 2 mg (48% 
yield) of 1.95 (a crystalline solid).The structure was confirmed by taking X-ray. Based on this X-
ray structure the earlier products (1.94 and 1.93) were characterized. 1H NMR (CDCl3) δ 5.1 (tt, 
J = 8 Hz, 1 H, =CH), 3.85 (s, 1 H, CHOMe), 3.62 (t, J = 6 Hz, 1 H, CHO), 3.51 (s, 3 H, OMe), 
3.38 (d, J = 5 Hz, 1 H, CHO), 2.95 (d, J = 5 Hz, 1 H, CHO), 2.7 (m, 2 H, CH2), 2.26 (m, 2 H, 
CH2), 2.10 (m, 2 H, CH2), 1.714 (s, 3 H, CH3), 1.711 (s, 3 H, CH3), 1.324 (s, 3 H, CH3), 1.53 (m, 
1 H, CH). 
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X-ray crystal structure of compound 1.95. 
 
(-)-Camphanoyl Chloride (1.99) (SB-3-83)44 
O
O
O Cl  
 
A round bottom flask was equipped with a drying tube and was charged with 4.58 g (0.0232 mol) 
of (-)-camphanic acid (1.98). To this flask 13.5 mL (0.197 mmol) of thionyl chloride was added 
dropwise. Then a reflux condenser was attached to the flask and the resulting solution was heated 
to reflux for three hours. The flask was cooled to room temperature and excess thionyl chloride 
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was removed under vaccum. Later 2 mL of benzene was added to the mixture and azeotropic off 
the remaining thionyl chloride leaving 4.37 g (87% yield) of the pure chloride 1.99. 1H NMR 
(CDCl3) δ 2.48 (m, 1 H, CH), 2.19 (m, 1 H, CH), 1.99 (m, 1 H, CH), 1.77 (m, 1 H, CH), 1.15 (s, 
3 H, Me), 1.14 (s, 3 H, Me), 1.13 (s, 3 H, Me); 13C NMR (CDCl3) δ 176.9, 171.9, 95.1, 90.1, 
55.13, 31.6, 30.8, 28.9, 16.8, 9.8. 
 
3-Methylene-6-((-)-(1S,4R)-camphanoyloxy)cyclohexene (1.70) (SB-3-99) 
      Ocamp
1
2
3
4
5
6
7
 
To a solution of 1.6 g (0.0145 mol) of alcohol 1.70 in 50 mL CH2Cl2 was added 4.69 mL (0.058 
mol) of pyridine and cooled to 0 0C. Then 0.1772 g (0.00145 mol) of DMAP was added to the 
above mixture and allowed to stir for 10 min at 0 0C. Then 3.782 g (0.01745 mol) of (-)-(1S,4R)-
camphanoyl chloride was added and slowly allowed the reaction mixture to warm to room 
temperature and stirred the reaction mixture at room temperature for 12 hours. The progress of 
the reaction was monitored by TLC using hexane and ethyl acetate (1:1 v/v) as a developing 
solvent. This reaction mixture was washed with 1 M HCl and extracted using diethyl ether. Then 
the organic layer was washed with aqueous NaHCO3 and brine. The organic layer was dried over 
anhydrous sodium sulfate, filtered and concentrated. Column chromatographic separation on 
silica gel using hexane and ethyl acetate (1:1) as an eluent afforded 3.6 g (86% yield) of 1.100. 
1H NMR (CDCl3) δ 6.3 (dd, J = 3 Hz, 1 H, =CH), 5.8 (q, J = 6 Hz, 1 H, =CH), 5.5 (m, 1 H, 
CHO), 4.95 (s, 2 H, =CH2), 2.42 (m, 2 H, CH2), 2.05 (m, 2 H, CH2), 1.95 (m, 2 H, CH2), 1.67 (m, 
2 H, CH2), 1.08, (s, 3 H, CH3), 1.02 (s, 3 H, CH3), 0.931 (s, 3 H, CH3), 0.927 (s, 3 H, CH3); 13C 
NMR 178, 167.1, 141, 133.89, 133.86, 126.2, 126.1, 114.38, 114.35, 91.149, 69.56, 69.47, 54.85, 
54.22, 30.66, 30.58, 29.09, 29.06, 28.35, 26.12, 26.58, 16.91, 16.84, 16.78, 9.76. 
 
(3R*,8R*) and (3R*,8S*)-6-(t-Butyldimethylsilyloxy)-1-oxaspiro[2.5] oct-4-ene (1.106 & 
1.62) (SB-5-96) 
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A round bottom flask was charged with 10.5 g (0.0468 mol) of 1.63 in 125 mL of EDTA (4 x10-4 
M) to CH3CN + THF (8:2) in 9:11 ratio and the round bottom was cooled to 0 0C. The round 
bottom was equipped with a dewar condenser on the top. It is very necessary to cool the dewar 
flask to -78 0C throughout the reaction period to avoid the escape of low boiling liquids (1,1,1-
trifluoroacetone) which are added in due course (two additions of 1,1,1-trifluoroacetone). Then 
19.67 g (0.234 mol) of sodium bicarbonate was added to the above mixture at 0 0C. Then 2.53 
mL (0.0269 mol) of 1,1,1-trifluoroacetone was added via syringe followed by 14.38 g (0.0234 
mol) of oxone was added over 20 minutes in portions. The resulting mixture was stirred at 0 0C 
for one hour. Then another half portion of 2.53 mL (0.0269 mol) of 1,1,1-trifluoroacetone was 
added and the reaction was maintained at 0 0C. This mixture was stirred at 0 0C for 6 hours. The 
dry ice dewar is to be maintained at -78 0C always. The progress of the reaction was monitored 
by TLC using hexane and diethyl ether (1:1 v/v) as a developing solvent. The reaction mixture 
doesn’t go to completion. If we run it for a long time there is always a risk of decomposition of 
epoxide. The reaction mixture was diluted with CH2Cl2 and washed with aqueous sodium sulfate. 
The organic layer was washed with brine and dried over anhydrous sodium sulfate. The silica gel 
was used to perform column chromatography. Hexane was mixed with silica gel along with 1% 
triethylamine and sonicated for one hour. Column chromatographic separation on silica gel using 
hexane and diethyl ether (1:1 v/v) as an eluent afforded 9.1 g (82%) of mixture of epoxides 1.106 
and 1.62 in 1:1 ratio. The ratio of the two isomers was based on the integration from the proton 
NMR. The starting material the diene 1.63 (9%) was recovered. It is difficult to assign which set 
of proton and 13C NMR’s belong to which isomer. 1H NMR (CDCl3) (of one isomer): δ 6.0 (d, J 
= 10Hz, 1 H, =CH), 5.22 (t, J = 10 Hz, 1 H, =CH), 4.35 (1 H, HC-OSi), 2.84 (d, J = 5 Hz, 1 H, 
OCH2), 2.76 (d, J = 5 Hz, 1 H, OCH2), 1.91 (m, 2 H, CH2), 1.7 (m, 2 H, CH2), 0.89 (s, 9 H, t-Bu), 
0.03 (s, 3 H, SiCH3), 0.03 (s, 3 H, SiCH3); 1H NMR (CDCl3) (of another isomer) δ 6.0 (d, J = 
10Hz, 1 H, =CH), 5.22 (t, J = 10 Hz, 1 H, =CH), 4.28 (1 H, HC-OSi), 2.84 (d, J = 5 Hz, 1 H, 
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OCH2), 2.76 (d, J = 5 Hz, 1 H, OCH2), 1.91 (m, 2 H, CH2), 1.7 (m, 2 H, CH2), 0.89 (s, 9 H, t-Bu), 
0.03 (s, 3 H, SiCH3), 0.03 (s, 3 H, SiCH3); 13C NMR (CDCl3) (of one isomer): δ 139.4, 129.99, 
66.8, 55.3, 31.7, 27.8, 26.0,18.3, -4.4, -4.48. 13C NMR (CDCl3) (of another isomer): δ 138.2, 
128.8, 65.9, 54.9, 30.9, 27.8, 26.0, 18.3, -4.4, -4.48. 
 
 
(3S*,4S*,5R*,6R*)-6-(tert-Butyldimethylsilyloxy)-1-oxaspiro[2.5]octane-4,5-diol (1.108) & 
(3S*,4R*,5S*,6S*)-6-(tert-butyldimethylsilyloxy)-1-oxaspiro[2.5]octane-4,5-diol (1.107) (SB-
5-97) 
     
OTBDMS
O
OTBDMS
O
OH
OH
OH
OH
1.107 1.108  
 
To a solution of 9 g (0.0374 mol) of mixture of epoxides (1.106 and 1.62) in 665 mL of acetone-
water (3:1) 90 mL of tert-butanol was added. To this mixture 13.14 g (0.1123 mol) of NMO was 
added followed by catalytic amount of 0.5 g of osmium tetraoxide was added and stirred at room 
temperature. This mixture was stirred at room temperature for 36 hours. The progress of the 
reaction was monitored by TLC using hexane and ethyl acetate as a developing solvent. In order 
to get rid of acetone in the solution, distillation was performed. Then the resulting solution was 
washed with water and extracted with CH2Cl2. The organic layers were washed with brine, dried 
over anhydrous sodium sulfate and concentrated. Column chromatographic separation on silica 
gel using mixture of hexane and diethyl ether (1:1 v/v) afforded 65 % of two cis diols 1.107 and 
1.108 in 1:1 ratio. The ratio of the two compounds was based on integration in proton NMR. 
These two isomers were not separable by column chromatography at this stage. We couldn’t find 
suitable solvent system to separate them efficiently. The identification of the two alcohols is 
carried by derivatization in the next step. 1H NMR (CDCl3) (of one isomer) δ 3.99 (m, 1H, 
CHOTBDMS), 3.82 (m, 1 H, CHOH), 2.94 (d, J = 5 Hz, 1 H, OCH2), 2.6 (d, J = 5 Hz, OCH2), 
2.42 (d, J = 6 Hz, 1 H, CHOH), 1.85 (m, 2 H, CH2), 1.5 (m, 2 H, CH2), 0.91 (s, 9 H, t-Bu), 0.11 
(s, 3 H, CH3), 0.10 (s, 3 H, CH3); 1H NMR (CDCl3) (of another isomer) δ 3.99 (m, 1H, 
CHOTBDMS), 3.82 (m, 1 H, CHOH), 3.02 (d, J = 3 Hz, 1 H, OCH2), 2.91 (d, J = 4 Hz, OCH2), 
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2.83 (d, J = 5 Hz, 1 H, CHOH), 1.85 (m, 2 H, CH2), 1.5 (m, 2 H, CH2), 0.91 (s, 9 H, t-Bu), 0.11 
(s, 3 H, CH3), 0.10 (s, 3 H, CH3); 13C NMR (CDCl3) (of one isomer) δ 75.8, 71.4, 70.62, 59.6, 
51.4, 28.8, 26.91, 26.07, 18.18, -4.29, -4.62; 13C NMR (CDCl3) (of another isomer) δ 74.6, 71.16, 
70.62, 59.0, 49.7, 28.8, 26.39, 25.96, 14.41, -4.48, -4.62. 
 
 
(3S*,4S*,5R*,6R*)-6-(tert-Butyldimethylsilyloxy)-5-hydroxy-1oxaspiro[2.5]octan -4-yl 
benzoate (1.109) (SB-5-99) 
      OTBDMS
O
OCOPh
OH
12
3
4
5
6
 
 
To a solution of 6.7 g (0.0245 mol) of mixture of 1.107 and 1.108 (in 1:1 ratio) in 150 mL THF 
was added 10.2 mL (0.073 mol) of triethylamine and the solution was stirred at 0 0C for 10 
minutes. Then 3.1 mL (0.027 mol) of benzoyl chloride was added to the solution and stirred at 0 
0C for one hour and allowed to reach room temperature slowly. This solution was stirred at room 
temperature for 12 hours. The resulting solution was washed with 1 M HCl and extracted with 
methylene chloride. The organic layer was washed with aqueous NaHCO3 and brine, dried over 
anhydrous sodium sulfate, filtered and concentrated. Column chromatographic separation on 
silica gel using mixture of hexane and ethyl acetate (1:1 v/v) afforded unreacted 1.107 in 49% 
yield and benzoylated product 1.109 in 43% yield. The alcohol at C4 position is benzoylated  in 
compound 1.108, which is confirmed from proton NMR as we see a doublet signal at δ 5.49. The 
absence of a multiplet in the same region confirms that the C5 alcohol is not benzoylated. 1H 
NMR of 1.109 (CDCl3) δ 8.07 (d, J = 7 Hz, 2 H, Ar), 7.58 (d, J = 3 Hz, 1 H, Ar), 7.49 (t, J = 7 
Hz, 2 H, Ar), 5.49 (d, J = 3 Hz, 1 H, CHOCOPh), 4.13 (m, 1 H, CHOTBDMS), 3.98 (m, 1 H, 
CHOH), 2.82 (d, J = 5 Hz, 1 H, CHO), 2.61 (d, J = 5 Hz, 1 H, CHO), 2.14 (t, J = 8 Hz, 2 H, CH2), 
1.66 (m, 2 H, CH2), 0.94 (s, 9 H, t-Bu), 0.126 ( s, 3 H, CH3), 0.119 (s, 3 H, CH3); 13C NMR 
(CDCl3) δ 152.5, 141.5, 133.5, 130.0, 128.7, 74.5, 71.2, 70.6, 58.8, 49.6, 27.1, 26.8, 25.9, 18.2, -
4.5, -4.7. 1H NMR of 1.107 (CDCl3) δ 3.99 (m, 1H, CHOTBDMS), 3.82 (m, 2 H, CHOH), 2.94 
(d, J = 5 Hz, 1 H, OCH2), 2.69 (d, J = 5 Hz, OCH2), 2.42 (m, 1 H, CH), 2.33 (m, 1 H, CH), 1.75 
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(m, 2 H, CH2), 0.91 (s, 9 H, t-Bu), 0.11 (s, 3 H, CH3), 0.10 (s, 3 H, CH3); 13C NMR (CDCl3) δ 
74.8, 70.36, 70.01, 59.6, 51.1, 28.3, 26.3, 25.8, 17.9, -4.7, -4.8. 
 
(3S*,4S*,5R*,6R*)-6-(tert-Butyldimethylsilyloxy)-5-methoxy-1-oxaspiro[2.5]octan -4-yl 
benzoate (1.110) (SB-5-102) 
      OTBDMS
O
OCOPh
OMe
12
3
4
5
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To a solution of 2.23 g (5.65 mmol) of 1.109 in 50 mL of CH2Cl2 was added 2.9 g (13.57 mmol) 
of proton sponge at 0 0C. The reaction mixture was stirred for 15 minutes at 0 0C and then 1 g 
(6.78 mmol) of trimethyloxonium tetrafluoroborate was added in portions and stirred at 0 0C for 
half an hour. The reaction mixture was allowed to reach room temperature was stirred for 48 
hours. The progress of the reaction was monitored by TLC using hexane and diethyl ether (1:1 
v/v) as a developing solvent. The reaction mixture was washed with 1 M HCl and extracted with 
diethyl ether. The organic layer was washed with aqueous sodium bicarbonate and brine, dried 
over anhydrous sodium sulfate, concentrated and the residue was applied to column 
chromatography (silica gel). Mixture of hexane and diethyl ether (1:1 v/v) was used as an eluent 
to obtain 1.25 g (72 % yield) of title compound 1.110. 1H NMR of (CDCl3) δ 8.07 (d, J = 7 Hz, 2 
H, Ar), 7.59 (t, J = 7 Hz, 1 H, Ar), 7.45 (t, J = 8 Hz, 2 H, Ar), 5.45 (d, J = 3 Hz, 1 H, CHOCOPh), 
4.09 (m, 1 H, CHOTBDMS), 3.4 (s, 3 H, OMe), 3.36 (m, 1 H, CHOMe), 2.81 (d, J =5 Hz, 1 H, 
CHO), 2.63 (d, J = 5 Hz, 1 H, CHO), 2.12 (m, 1 H, CH), 1.96 (m, 1 H, CH), 1.62 (m, 1 H, CH), 
1.58 (m, 1 H, CH), 0.92 (s, 9 H, t-Bu), 0.097 (s, 3 H, SiMe), 0.091 (s, 3 H, SiMe); 13C NMR 
(CDCl3) δ 165.8, 133.3, 130.3, 130.0, 128.6, 83.7, 71.7, 69.8, 58.7, 58.2, 50.7, 28.8, 27.0, 25.99, 
18.3, -4.5, -4.8. 
 
(3S*,4S*,5R*,6R*)-6-(tert-Butyldimethylsilyloxy)-5-methoxy-1-oxaspiro[2.5]octan -4-ol 
(1.111) (SB-5-104) 
      OTBDMS
O
OH
OMe
12
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To a solution of 1.25 g (3.061 mmol) of 1.110 in 60 mL of distilled anhydrous methanol was 
added 1.06 g (7.65 mmol) of potassium carbonate at 0 0C. The reaction mixture was stirred at 0 
0C for 5 hours. The solid reside in the mixture from potassium carbonate was filtered through a 
pad of celite and the resulting mixture was evapourated using a rotavapor to get rid of methanol. 
Then the residue was diluted with CH2Cl2 and washed with 1 M HCl, aqueous NaHCO3 and 
brine. The organic layers were dried over anhydrous sodium sulfate, filtered and evapourated. 
Column chromatographic separation on silica gel using mixture of hexane and ethyl acetate (1:1 
v/v) afforded 730 mg (79% yield) of 1.111. 1H NMR (CDCl3) δ 4.18 (m, 1 H, CHOTBDMS), 
3.97 (dd, J = 4 Hz, 1 H, CHOH), 3.45 (s, 3 H, OMe), 3.34 (t, J = 4 Hz, 1 H, CHOMe), 2.89 (d, J 
= 6 Hz, 1 H, OCH2), 2.43 (d, J = 5 Hz, 1 H, OCH2), 2.2 (m, 2 H, CH2), 1.48 (m, 2 H, CH2), 0.9 (s, 
9 H, t-Bu), 0.1 (s, 3 H, SiMe), 0.089 (s, 3 H, SiMe); 13C NMR (CDCl3) δ 83.9, 67.9, 66.3, 59.1, 
58.7, 48.5, 26.4, 26.05, 25.9, 18.2, -4.7, -4.74. 
 
(3S*,4S*,5R*,6R*)-6-(tert-Butyldimethylsilyloxy)-5-methoxy-1-oxaspiro[2.5]octan -4-one 
(1.112) (SB-6-22) 
      OTBDMS
O
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To a solution of 305 mg (1.0 mmol) of 1.111 in a solution of 20 mL of distilled DMSO was 
added 422.2 mg (1.508 mmol) of o-iodoxybenzoic acid (IBX) at room temperature. The reaction 
was stirred at room temperature for 12 hours. The resultant solution was washed with water and 
extracted with CH2Cl2. The organic layer was washed with brine and dried over anhydrous 
sodium sulfate and concentrated to dryness under vacuum. Column chromatographic separation 
on silica gel using mixture of hexane and ethyl acetate (1:1) afforded 283 mg (94% yield) of 
1.112. 1H NMR (CDCl3) δ 3.83 (m, 1 H, CHOTBDMS), 3.47 (d, J = 8 Hz, 1 H, CHOMe), 3.4 (s, 
3 H, OMe), 2.8 (d, J = 6 Hz, 1 H, OCH2), 2.67 (d, J = 6 Hz, 1 H, OCH2), 2.1 (m, 2 H, CH2), 1.7 
(m, 2 H, CH2), 0.8 (s, 9 H, t-Bu), 0.01 (s, 3 H, SiCH3), 0.01 (s, 3 H, SiCH3); 13C NMR δ 206, 
90.3, 73.5, 60.3, 53.8, 29.7, 27.1, 25.9, -4.45, -4.83. 
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(3S*,4R*,5S*,6S*)-6-(tert-Butyldimethylsilyloxy)-5-methoxy-1-oxaspiro[2.5]octan -4-o1 
(1.114), (3S*,4R*,5S*,6S*)-6-(tert-butyldimethylsilyloxy)-4-methoxy-1-oxaspiro[2.5]octan -
5-o1 (1.115), (3S*,4R*,5S*,6S*)-6-(tert-butyldimethylsilyloxy)-4,5-dimethoxy-1-
oxaspiro[2.5]octane (1.116). (SB-8-94) 
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To a solution of 900 mg (3.279 mmol) of 1.107 in 15 mL of methylene chloride was added 1.83 
g (8.526 mmol) of 1,8-bis(dimethylamino)naphthalene (proton sponge) and the reaction mixture 
was stirred at 0 0C for 15 minutes. Then 0.727 g (4.919 mmol) of trimethyloxonium 
tetrafluoroborate was added to this solution at 0 0C. The resulting solution was stirred at room 
temperature for 48 hours. The reaction mixture was washed with 1 M HCl and extracted with 
CH2Cl2. The organic layer was washed with aqueous sodium bicarbonate and brine, dried over 
anhydrous sodium sulfate, filtered and concentrated to dryness. Column chromatographic 
separation on silica gel using gradient mixture of hexane and ethyl acetate (1:1 v/v) afforded 149 
mg (15% yield) of 1.116, two monomethylated products 1.114 and 1.115 in 80% yield (in 1:1 
ratio based on the crude proton NMR)and recovered 45 mg (5%) of starting material 1.107 was 
recovered. Based on proton NMR we can distinguish the two compounds 1.114 and 1.115. 
Compound 1.115 shows a doublet at δ 3.33 for C4 hydrogen where as compound 1.114 shows a 
doublet of a doublet at δ 3.34 for C4 hydrogen. Another column chromatographic separation 
using hexane and ethyl acetate (1:1 v/v) was used as an eluent to separate the monomethylated 
products but couldn’t separate them efficiently. 1H NMR of 1.114 (CDCl3) δ 3.99 (m, 1 H, 
CHOTBDMS), 3.82 (s, 1 H, CHOH), 3.45 (s, 3 H, OMe), 3.4 (m, 1 H, CHOMe), 2.9 (d, J = 5 Hz, 
1 H, CHO), 2.67 (d, J = 5 Hz, 1 H, CHO), 2.32 (d, 1 H, OH), 1.85 (m, 2 H, CH2), 1.67 (m, 2 H, 
CH2), 0.91 (s, 9 H, t-Bu), 0.1 (s, 3 H, CH3), 0.089 (s, 3 H, CH3); 13C NMR of 1.114 (CDCl3) δ 
84.5, 70.3, 68.6, 59.2, 58.8, 51.5, 30.5, 29.1, 26.2, 25.9, 18.3, -4.6. 
1H NMR of 1.115 (CDCl3) δ 3.95 (m, 1 H, CHOTBDMS), 3.81 (s, 1 H, CHOH), 3.42 (s, 3 H, 
OMe), 3.34 (m, 1 H, CHOMe), 2.93 (d, J = 5 Hz, 1 H, CHO), 2.68 (d, J = 5 Hz, 1 H, CHO), 2.36 
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(d, 1 H, OH), 1.90 (m, 2 H, CH2), 1.63 (m, 2 H, CH2), 0.91 (s, 9 H, t-Bu), 0.11 (s, 3 H, CH3), 
0.089 (s, 3 H, CH3); 13C NMR of 1.114 (CDCl3) δ 80.4, 74.3, 70.6, 58.6, 58.0, 51.9, 29.1, 28.7, 
26.6, 26.2, 25.9, 18.2, -4.4, -4.6. 
1H NMR of 1.116 (CDCl3) δ 4.03 (m, 1 H, CHOTBDMS), 3.45 (s, 3 H, OMe), 3.41 (s, 3 H, 
OMe), 3.37 (s, 1 H, CHOMe), 3.35 (s, 1 H, CHOMe), 2.95 (d, J = 5 Hz, 1 H, CHO), 2.71 (d, J = 
5 Hz, 1 H, CHO), 1.85 (m, 2 H, CH2), 1.65 (m, 2 H, CH2), 0.91 (s, 9 H, t-Bu), 0.11 (s, 3 H, CH3), 
0.09 (s, 3 H, CH3); 13C NMR of 1.116 (CDCl3) δ 83.9, 79.7, 69.1, 59.1, 58.6, 58.3, 52.3, 29.3, 
26.5, 26.0, 18.3, -4.54, -4.59. 
 
(3S*,5S*,6S*)-6-(tert-Butyldimethylsilyloxy)-5-methoxy-1-oxaspiro[2.5]octan -4-one (1.117) 
(SB-8-87) 
     
O
OMe
OTBDMS
O
12
3 4
56
 
 
To a solution of 10 mg (0.0329 mmol) of 1.114 in 0.5 mL of DMSO under argon, was added 12 
mg (0.043 mmol) of IBX. The reaction mixture was stirred at room temperature for 12 hours. 
The reaction mixture was washed with water and extracted with CH2Cl2. The organic layer was 
washed with brine, dried over anhydrous sodium sulfate and concentrated to dryness. Column 
chromatographic separation on silica gel using gradient mixture of hexane and ethyl acetate (1:1 
v/v) afforded 9 mg (90% yield) of 1.117. 1H NMR (CDCl3) δ 4.17 (m, 1 H, CHOTBDMS), 3.51 
(d, J = 4.8 Hz, 1 H, C5-H), 3.29 (s, 3 H, OMe), 2.87 (d, J = 1.2 Hz, 1 H, CHO), 2.85 (d, J = 1.2 
Hz, 1 H, CHO), 2.3 (m, 2 H, CH2), 1.6 (m, 2 H, CH2), 0.85 (s, 9 H, t-Bu), 0.66 (s, 6 H, 2 CH3); 
13C NMR of 1.117 (CDCl3) δ 203.6, 86.9, 71.4, 59.6, 58.3, 54.2, 27.4, 26.9, 25.8, 18.1, -4.8. 
 
(3S*,4R*,5S*,6S*)-4-(1’,5’-Dimethylhexa-1’,4’-dienyl)-5-methoxy-6-(tert-
butyldimethylsilyloxy)-1-oxaspiro[2.5]octan-4-ol (1.119) and (3S*,4S*,5S*,6S*)-4-(1’,5’-
dimethylhexa-1’,4’-dienyl)-5-methoxy-6-(tert-butyldimethylsilyloxy)-1-oxaspiro[2.5]octan-
4-ol (1.120) (SB-6-48) 
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O
OMe
OTBDMS
12
3 4
56
OH
O
OMe
OTBDMS
12
3 4
56
OH
1.119 1.120  
 
To a solution of 70 mg (0.2326 mmol) of 1.112 in 1 mL ether and 1 mL toluene was added 
0.9302 mmol of alkenyl lithium 1.11 at -78 0C under argon. This solution was stirred at -78 0C 
for one hour and slowly allowed to reach to room temperature. The progress of the reaction was 
monitored by TLC using hexane and ethyl acetate as a developing solvent. The resulting solution 
was washed with aqueous ammonium chloride and extracted with CH2Cl2. The organic layer was 
washed with brine, dried over anhydrous sodium sulfate. Column chromatographic separation on 
silica gel using gradient mixture of hexane and ethyl acetate (1:1 v/v) afforded 72 mg (75% yield) 
of a mixture of compounds 1.119 and 1.120. These two isomers were inseparable by column 
chromatography. From the proton NMR it is clear that there are two compounds in about ~1:2 
ratio (based on proton NMR integration). Two distinct signals appear for C2 hydrogen’s and C5 
hydrogen’s. Apart from that two sets of signals appear for methyl groups on side chain (δ 1.743, 
1.689, 1,625 for one set and δ 1.7303, 1.679, 1.613 ), two signals for tert-Si group (δ 0.909 for 
one compound and 0.884 for another compound) and two sets of signals for silyl-methyl groups 
(δ 0.113, 0.0867 for one compound and δ 0.0794, 0.0684 for another compound). Two sets of 
doublets are also observed for methylene group of epoxide. This confirm the presence of two 
compounds. It is hard to assign peaks which correlate to the respective compound. It is also 
difficult to decide which compound is in larger portion in this mixture. So here in we report two 
sets of proton NMR data. 1H NMR (CDCl3) (one compound which is a major fraction in the 
mixture) δ 5.99 (m, 1 H, C=C-H), 5.13 (m, 1 H, H-C=C), 4.09 (m, 1 H, CHOTBDMS), 3.54 (s, 3 
H, OMe), 3.48 (s, 1 H, CHOMe), 3.08 (d, J = 12 Hz, 1 H, CHO), 2.345 (d, J = 7 Hz, 1 H, CHO), 
2.05-1-95 (m, 2 H, CH2), 1.743 (s, 3 H, Me), 1.689 (s, 3 H, Me), 1.625 (s, 3 H, Me), 1.30-1.20 
(m, 2 H, CH2), 0.909 (s, 9 H, t-Bu), 0.113 (s, 3 H, Me), 0.0867 (s, 3 H, Me); 1H NMR (CDCl3) 
(another compound which is a minor fraction in the mixture) δ 5.45 (m, 1 H, C=C-H), 5.1 (m, 1 
H, H-C=C), 4.09 (m, 1 H, CHOTBDMS), 3.54 (s, 3 H, OMe), 3.5 (s, 1 H, CHOMe), 2.965 (d, J 
= 2 Hz, 1 H, CHO), 2.729 (d, J = 7 Hz, 1 H, CHO), 2.05-1-95 (m, 2 H, CH2), ), 1.7303 (s, 3 H, 
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Me), 1.679 (s, 3 H, Me), 1.613 (s, 3 H, Me), 1.30-1.20 (m, 2 H, CH2), 0.884 (s, 9 H, t-Bu), 0.079 
(s, 3 H, Me), 0.068 (s, 3 H, Me). 
 
(3S*,4S*,5S*,6S*)-4-(2’-Methyl-3’-(3’’-methylbut-2’’-enyl)oxiran-2’-yl)-5-methoxy-6-(tert-
butyldimethylsilyloxy)-1-oxaspiro[2.5]octan-4-ol (1.122) (SB-6-60) 
     
O
OMe
OTBDMS
12
3 4
56
O
OH
 
 
To a solution of 24 mg (0.0584 mmol) of mixture of 1.119 and 1.120 in 1 mL of benzene was 
added 2.167 mg (0.0082 mmol) of vanadly acetylacetonate (a solution in 2 mL of benzene) and 
1.16 mL of 0.1 M tert-butyl hydroperoxide (commercially available from aldrich) at room 
temperature. The reaction mixture was stirred at room temperature for 2 hours. The organic layer 
was washed with 10% sodium thiosulfate and extracted with ether three times. The organic layer 
was washed with brine, dried over anhydrous sodium sulfate and concentrated to dryness. The 
crude NMR shows the presence of some starting material but reveals the formation of product. 
Column chromatographic separation on silica gel using a mixture of hexane and ethyl acetate 
(1:1 v/v) afforded 2 mg of compound 1.122 (8%). Besides the above product 12 mg (50%) of 
starting material 1.119 and 1.120 and some unidentified materials (8%) were recovered. We were 
unable to determine the stereochemistry of this compound at C4 position at this stage. Removal 
of TBDMS group and oxidation of thus formed alcohol to ketone may help us to determine the 
stereochemistry by comparing with compound 1.95. 1H NMR (CDCl3) δ 5.14 (m, 1 H, H-C=C), 
4.02 (m, 1 H, CHOTBDMS), 3.6 (s, 3 H, OMe), 3.23 (d, J = 8 Hz, 1 H, CHOMe), 3.11 (t,  J = 8 
Hz, 1 H, O-CH-CH2), 3.01 (s, 1 H, OH), 2.77 (m, 1H, CHO), 2.50 (d, J = 5 Hz, 1H, CHO), 2.27 
(m, 2H, CH2), 2.11 (m, 1H, CH), 1.87 (m, 1H, CH), 1.683 (s, 3 H, CH3), 1.68 (s, 3H, CH3), 1.29 
(s, 3 H, CH3), 0.877 (s, 9 H, t-Bu), 0.092 (s, 3 H, SiMe), 0.07 (s, 3 H, SiMe). 
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CHAPTER 2 – Novel tricyclic pyrone compounds protect cell death 
induced with intracellular Aβ oligomeric complexes 
 
2.1 Introduction 
Protein aggregation may lead to many neurodegenerative diseases such as Alzhemier’s 
disease (AD), Parkinson’s disease (PD), Huntington’s disease (HD), amyotropic lateral sclerosis 
(ALS) and prion diseases.1 Most active research has been carried out in these areas as these 
diseases are characterized by loss of synaptic connections and aggregation of proteins both 
intracellular and extracellular.1 The deposition of aggregated protein in different areas of brain 
can cause different kinds of neurodegenerative diseases. Deposition of different type of proteins 
and pathology is depicted in the following table (shown in Table 2.1).1 Each and every disease 
has its own reasons and symptoms and can occur in either in middle age or in old age of a person 
and eventually leading to death. There is no effective treatment or cure.2 Early detection is not 
easy as the symptoms are exhibited only after death of many neurons and certain parts of brain 
are weakened.2 Factors that attribute to this neuron death are “excitotoxicity, cellular calcium 
overload, mitochondrial dysfunction, oxidative stress” etc.2  
As per statistics there are 4 million people who suffer from AD, 1 million from PD, 
350,000 from multiple sclerosis and 20,000 from ALS in United States.2 There are 20 million 
patients who suffer from these four diseases worldwide.2 “AD, a irreversible disease with no cure 
is the third most costly disease in US after heart disease and cancer”.3 “Federal government spent 
$647 million for AD research in the year 2005”.3 After viewing this it is very important to 
address the exact cause and prevention and curative measures for this AD disease.  
 
2.2 Back ground and Significance 
 Alzhemier’s disease (AD) is characterized by loss of memory, speech, recognition of 
people and objects, etc.1, 4 This is because of fibrillar amyloid deposits in the brains of 
alzhemier’s patients. An AD patient’s brain has two kinds of classical lesions, extracellular 
senile (neuritic) plaques and intracellular nuerofibrillary tangles.Extracellular deposits (plaques) 
consist of Aβ peptides and intracellular deposits (tangles) are Aβ tau protein.5 Aβ peptide is a 
fragment of another protein called amyloid precursor protein (APP). In a normal persons brain 
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these deposits are eliminated whereas in AD patient they accumulate as plaques.6 Tau proteins 
are insoluble proteins inside neurons, a subset of microtubles (helps transport of nutrients within 
neurons) aggregates in a AD patient (Figure 2.1).6 
 
         
Disease 
          
Etiology 
  
 Regions most 
affected 
   
Characteristic   
pathology            
 
Disease 
proteins     
deposited 
Huntington’s      
Disease 
Huntingtin 
(dominant) 
Striatum, other 
basal ganglia, 
cortex 
Intranuclear 
inclusions and 
cytoplasmic 
aggregates 
Huntingtin 
with 
polyglutamine 
expansion 
Other 
polyglutamine 
diseases 
(DRPLA, 
SCA1-3, etc., 
SBMA) 
Atrophin-1, 
ataxin-1-3, etc.; 
androgen receptor 
(AR) (dominant) 
Basal ganglia, 
brain stem 
cerebellum and 
spinal cord 
Intranuclear 
inclusions 
Atrophin-1, 
ataxins or AR 
Alzheimer’s 
Disease (AD) 
Sporadic (ApoE 
risk factor) 
 
 
 
 
Amyloid 
precursor protein 
(APP) (dominant) 
 
 
Presenilin1,2 
(dominant) 
Cortex, 
hippocampus, 
basal forebrain, 
brain stem  
 
 
Same as 
sporadic 
 
 
 
Same as 
spordaic 
Neuritic plaques 
& 
neurofibrillary 
tangles 
 
 
Same as 
sporadic 
 
 
 
Same as 
spordaic 
Aβ 
peptide(from 
APP)&,hyper
phopphorylate
d tau  
 
Same as 
sporadic 
 
 
 
Same as 
spordaic 
Fronto-
temporal 
dementia with 
parkinsonism 
Tau mutations 
(dominant) 
Frontal and 
temporal cortex, 
hippocampus 
Pick bodies Hyperphosph
orylated tau 
protein 
Parkinson’s 
Disease (PD) 
Spordaic 
 
 
 
α-Synuclein 
(dominant) 
 
 
 
Substantia 
nigra, 
cortex,locus 
ceruleus,etc 
Similar to 
sporadic, but 
more 
widespread 
 
Lewy bodies 
and Lewy 
neuritis 
 
Same as 
sporadic 
 
 
 
α-Synuclein 
 
 
 
α-Synuclein 
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Parkin (also DJ-1, 
PINK1) 
recessive (some 
dormant) 
 
 
Substantia nigra Lewy bodies 
absent (or much 
less frequent) 
α-Synuclein 
(when 
present) 
 
Amyotropic 
lateral sclerosis 
(ALS) 
Spordaic 
 
 
Superoxide 
dismutase-1 
(dominant) 
Spinal motor 
neurons and 
motor cortex 
 
Same as 
spordaic 
Bonina bodies 
and axonal 
spheroids  
 
Same 
Unknown 
(neurofilamen
ts) 
 
Unknown 
Prion diseases 
(kuru, CJD, 
GSS disease, 
fatal familial 
insomnia, new 
variant CJD) 
Spordaic, genetic 
and infectious 
Cortex, 
thalamus, brain 
stem, 
cerebellum, 
other regions 
Spongiform 
degeneration 
amyloid, other 
aggregates 
Prion protein 
ApoE, apolipoproteinE; APP, amyloid precursor protein; CJD, Creutzfeldt-Jakob disease; DRPLA, dentate-rubral 
and pallido-Luysian atrophy; GSS, Gerstmann-Straussler-Scheinker; SBMA, spinal and bulbar muscular atrpphy; 
SCA, spino-cerebellar ataxia 
Table 2.1 Neurodegenerative diseases: proteins and pathology 1 
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Figure 2.1 Amyloid plaques and neurofibrillary tangles shown in Alzhemier’s case and these 
aggregrates are absent in normal case (This picture is taken from reference without permission).6 
 
 The following figure 2.2 depicts how the some parts of brain shrinks as the disease 
progresses.7 In early stages of this disease ventricles are enlarged and the hippocampus cells 
begin to degenerate and shrink which markedly shows symptoms like relapse of short term 
memory etc.7 As the disease advances the cerebral cortex region shrinks along with hippocampus 
leaving patient with emotional outbursts and partial impairment.7 As the disease advances, the 
patient loses control over some vital organs and eventually leads him to death.7 
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Figure 2.2 Comparison of different brain parts at different stages of AD (This picture is taken 
from reference without permission).7 
 
 Amyloid β-protein (Aβ) is the major constituent of fibrillar deposits in AD patients. It is 
hypothesized that the production of Aβ in the brain is increased by disease-associated mutations 
and risk factors which is proven when Aβ fibrils killed the neuron cells when added in vitro. 
Therefore AD pathogenesis is caused by generation of extracellular Aβ fibrils. It is also 
hypothesized that the intraneuronal accumulation of Aβ is the first step of the amyloid cascade.8 
Also it is proven that intracellular Aβ induces more toxicity, atleast 10,000 times more toxic than 
extracellular Aβ.9, 10 Therefore it is important to decipher the mechanisms of the intraneuronal 
Aβ aggregates that induces toxicity.  
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 Aβ is a subunit of a large precursor called amyloid-β precursor protein (APP) consisting 
of 770 amino acids. APP is first cleaved by β-secretase to produce a 99-residue COOH-terminal 
membrane fragment called C99. Later this C99 fragment is cleaved by γ-secretase to produce 
either a 40 reside (Aβ40) or a 42 residue (Aβ42) peptide. This Aβ fragment has 28 amino acids 
outside the membrane and 12-14 amino acids of transmembrane domain. C99 fragment can 
further be cleaved by α-secretase to generate a 83-residue COOH-terminal membrane fragment 
called C83 (Figure 2.3).5 Both Aβ40 and Aβ42 are hydrophobic and toxic and aggregate quickly. 
Based on biochemical and immunohistochemical studies, it is proven that Aβ42 has higher 
propensity for aggregation and fibrillogenesis.11 
 
 
Figure 2.3   β-Amyloid precursor protein (APP) and its metabolic derivatives (This picture was 
taken from the reference without permission).5 
 
 Aβ aggregation is a multitep process involving metastable intermediates including 
oligomeric complexes.12 Monomers quickly oligomerize to paranuclei. This paranuclei look like 
beads on a circular string comprising 5 to 6 monomers units. The Aβ aggregation starts with the 
formation of  paranuclei. This paranuclei can oligomerize to form large oligomers. There is 
always equilibrium between monomers, paranuclei and large oligomers.  Monomers, paranuclei 
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and large oligomers do not have any β sheets or turns, so are unstructured (U). On long standing 
these unstructured oligomers are converted to protofibrils (~ 5 nm). Protofibrils have β-sheets 
and turns. Finally step is the conversion of protofibrils to fibrils (~10 nm) which is an 
irreversible transformation (Figure 2.4).12 
 
 
Figure 2.4  Schematic diagram of conversion of a monomer to a fibril (This picture is taken from 
the reference without permission).12     
 
 The following diagram shows the hydrophobicty indexes of Aβ1 -43 peptide. The more 
positive units refer to the more hydrophobic β-sheet forming fragments. The more negative units 
refer to the more hydrophilic fragments (Figure 2.5).13 
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Figure 2.5   The hydrophobicity indexes of amyloid (1-43) sequence (This picture is taken from 
the reference without permission).13 
 
The Aβ oligomers is considered to be the most toxic form of oligomers14, accumulate in 
process of cultured APP transgenic mouse (Tg2576), within the endosomal vesicles and along 
microtubles.14-16 A recent report demonstrated that accumulation of Aβ in abnormal endosomes 
is because of increase in Aβ levels in AD.17 The development of Aβ oligomeric forms in neurons 
are responsible for neuritic damage and synaptic alterations.15, 16 It is also proven that 
intraneuronal Aβ accumulation occurs before the appearance of amyloid plaques.15, 18-20 From 
this data it is evident that Aβ accumulation and oligomerization in the endosomal compartments 
is toxic to neurons. So compounds that are cell permeable are indispensable to target 
intraneuronal Aβ.21 
 In the current study, we used MC65 cell lines as a convenient model for study of Aβ 
aggregation and toxicity and to screen bioactive compounds.22 MC65 is human neuroblastoma 
cell line that conditionally express a partial APP fusion protein termed SβC (C99) and die on 
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third day after transgene induction by removal of tetracycline (TC) from the media.23, 24 Later 
C99 is cleaved by γ-secretase to produce Aβ.15 Moreover MC65 cell toxicity is easily measured 
by simple MTT assay.15 
 It is been proven that several tricyclic pyrone (TP) compounds protects MC65 cells from 
death.25 TP compounds are structurally similar to pyripyropene A26 and arisugacin27, a 
cholesterol O-acyl-transferase inhibitor and a acetylcholineesterase inhibitor respectively. Using 
MC65 cell we screened many compounds, we selected a small molecule CP2 that protects MC65 
cells from death. CP2 was found to be lipophilic and cell permeable and block Aβ aggregation 
intracellularly.15 
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2.3 Synthesis of TP compounds 
2.3.1 Synthesis of CP2 
All the TP compounds are structurally similar to ACAT inhibitor, pyripyropene A 2.1. 
Several compounds were synthesized containing various functionalities.24 The key intermediate 
2.3 was synthesized by Dr. Yi Chen, a previous researcher in our group.28 Several analogues 
were designed by functionalizing at C3 and C7 positions. Dr. Yi Chen synthesized a TP 
compound via condensation. A cyclic enal and a pyrone were condensed in presence of L-proline. 
The condensation reaction afforded a tricyclic compound. Continuous efforts to synthesize an 
optically active pyrone were finally successful. Dr. Chen chose an asymmetric molecule (S)-(-)-
perillaldehyde to induce chirality in the tricyclic compounds. This aldehyde has an isopropylene 
group which is believed to induce stereochemistry in the TP product. Treatment of pyrone 2.5 
with (S)-(-)-perillaldehyde 2.4 with L-proline in ethyl acetate at 70 0C gave desired TP 
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compound in 78% yield. The structure was determined by single X-ray crystallographic 
analysis.28, 29 Surprisingly only one diastereomer was obtained (Scheme 2.1). Compound 2.3 was 
purified via recrystallization using ethyl acetate as a solvent. 
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Hydroxylation was carried out using 0.3 equiv. of BH3.THF followed by oxidation with 
hydrogen peroxide and hydrolysis of resultant borate with sodium hydroxide gave an inseparable 
mixture of two diastereomers alcohol 2.6 in 1:1 ratio. Hydroboration has to be performed at -20 
0C to selectively hydroborate the terminal double bond (Scheme 2.2). The presence of two 
isomers was confirmed by taking 13C NMR spectrum. This mixture was not separable by silica 
gel column chromatography. The mixture of alcohols 2.6 were mesylated. Treating compound 
2.6 with methanesulfonyl chloride in the presence of triethylamine afforded a mesylated product 
2.7 in 94% yield (Scheme 2.2). 
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 Mesylated product was heated with a highly polar compound adenine in the presence of 
DMA. Moreover adenine was known to be an active motif in some HIV agents. Mesylate 2.7 
was heated with dimethyl acetamide (DMA) and 1 equiv. of adenine to 150 0C for 7 hrs. DMA in 
the reaction mixture was distilled off.  Thus obtained brown residue was directly added to the 
silica gel column chromatography without any aqueous workup. Silica gel column 
chromatography yielded two compounds 2.2 and 2.8 in 10:1 ratio (Scheme 2.3). The compounds 
were characterized using 1H NMR and 13C NMR spectroscopy.24 
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 Silica gel column chromatographic separation did not yield pure CP2. We purified by 
using HPLC (Jupiter C18, 10-μ column (Phenomenex, Torrance, CA, USA)). The running 
solvent system was water and acetonitrile with 0.1% trifluoroacetic acid. After several attempts 
using different programs we finally able to separate the N-9’ analogue and CP2 in very pure 
form. We obtained CP2 as a trifluoracetic acid salt. This was later proved by 13C NMR and mass 
spectroscopy. We are unsure that how many trifluoro acetic acid molecules are adhering to one 
each molecule of CP2. Recently CP2 was structurally defined by using HMBC and HMQC 
experiments (unpublished results). 
 Mixture of alcohols 2.6 were brominated using carbon tetrabromide and triphenyl 
phosphine to obtain bromide 2.9. Bromide was stable on column and was purified by silica gel 
column chromatography (Scheme 2.4). Bromide 2.9 was heated to 150 0C in the presence of 
adenine and DMA. We obtained both N-3’and N-9’ analogues. 
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 Following the same procedure radio labeled CP2 was prepared from 14C- labeled adenine 
(was bought from Amersham Pharmacia Biotech, Piscataway, NJ, USA). We took 50 mg of non 
labeled adenine and dissolved in 10 mL ethanol and 10 mL double distilled water and heated on 
a hot plate. To the above solution 1 mL of labeled adenine (approximately 0.024 mg of 14C 
adenine) was added. This mixture was cooled to -78 0C and lyophilized. Thus obtained adenine 
was used to prepare radio labeled CP2 by similar method followed in scheme 2.4. 
 
2.3.2 Synthesis of CP2 analogues 
There are a number of sites in CP2 where modification can be done to increase the 
activity, increase the binding ability. Introduction of a lipophilic group at C-11 will allow the 
molecule to penetrate into blood brain barrier. The following figure shows the possible sites 
where a CP2 molecule can be modified. Modification should be done before introducing adenine 
group since the purification process after addition is a bit tedious. Different paths are designed 
starting from the vital intermediate compound 2.3 to construct different analogues. Functional 
group modification can be made at sites shown in figure 2.6. There are a number of synthetic 
analogues made by Dr. Chen28 and are tested. We synthesized different analogues and were 
tested for inhibition of Aβ aggregation. 
 
 85
O
O
O
H
N
N N
N
NH2
1
2
3
4
5a
6
7
8
9
10
11
12
13
14
*
*
* *
*
 
Figure 2.6 The symbol * indicates possible sites where CP2 can be modified. 
 
First in the series was adding an extra carbon atom at C-11. Treatment of compound 2.3 
with LDA at -78 0C yields a blue anionic species. Selective deprotonation of the C11 methyl 
group was done using LDA or n-BuLi and a subsequent addition of formaldehyde gave 25% 
(based on reacted 2.3) of alcohol 2.10. Anion generated at C11 will attack the aldehyde giving an 
alcohol 2.10. The low yield of the reaction can be attributed to many reasons. The primary 
reason is the insolubility of formaldehyde in any solvent. Efforts were made to increase the yield 
of the reaction but we weren’t successful. Formaldehyde was dried over P2O5 under vacuum 
before using. During the reaction, appearance of blue color solution confirms the formation of 
anion. HMPA was added to stabilize the anion. Anion was made to cannula to a formaldehyde-
THF solution and allowed to warm to room temperature. Aqueous workup and silica gel column 
chromatography yielded an alcohol 2.10 in 25% yield and a small amount of starting material 
compound 2.3 was recovered (Scheme 2.5). Alcohol is not stable at room temperature and soon 
decomposes to an unknown compound. Next step is carried out quickly without any further delay. 
Alcohol 2.10 was silylated using tert-butyldimethylsilyl chloride using imidazole as a base and 
DMAP as a catalyst to obtain a silylated product 2.11 in 97% yield (Scheme 2.5). 
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 Silylated product was selectively hydroxylated using BH3.THF at -20 0C followed by 
oxidation with hydrogen peroxide and hydrolysis of resultant borate with sodium hydroxide gave 
an inseparable mixture of two diastereomers alcohol 2.12 in 51% yield with recovery of some 
starting material 2.11. TBDMS protecting group was stable to these conditions. At this juncture 
we did not convert alcohol to bromide using carbon tetrabromide as this reaction releases acid 
HBr which will deprotect the TBDMS group. Alcohol was converted to a mesylate 2.13 using 
methanesulfonyl chloride and triethylamine as a base at 0 0C to give 98% yield (Scheme 2.6). 
Mesylate 2.13 was heated with adenine to 150 0C in presence of DMA. Desired product with an 
adenine substitution was expected. On silica gel column chromatography we did not obtain the 
desired product. We concluded that silyl protecting group is not an efficient protecting group and 
changed to the protecting group to acetate. 
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 We protected alcohol 2.10 with acetate protecting group. Treatment of alcohol 2.10 with 
acetic anhydride and pyridine as a base afforded to give compound 2.14 in quantitative yield. 
Selective hydroxylation using BH3.THF at -20 0C followed by oxidation with hydrogen peroxide 
and hydrolysis of resultant borate with sodium hydroxide gave an inseparable mixture of two 
diastereomers alcohol 2.15 with some starting material 2.14 recovery. Quick work up procedure 
was recommended. Sodium hydroxide (5% M) is recommended to keep the acetate group intact 
(Scheme 2.7). Alcohol 2.15 is converted both to mesylate 2.17 using methanesulfonyl chloride 
and bromide 2.16 using carbon tetrabromide (Scheme 2.8). Mesylated product 2.17 was proven 
to give best results on addition of adenine in the final step. 
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Mesylate 2.17 was heated to 150 0C with adenine and DMA for 7 hours. The reaction 
mixture was subjected to vacuum distillation to remove DMA. Resultant brown residue was 
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added to silica gel column chromatography for purification but obtained an impure product 2.18 
(Scheme 2.9). Compound 2.18 was purified by HPLC and the running solvent system was water 
and acetonitrile with 0.1% trifluoroacetic acid. Compound 2.18 was exhibiting similar activity 
when compared with CP2 and was also proven to inhibit the Aβ aggregation. Based on molecular 
modeling studies we concluded that the alcohol 2.19 will enhance the activity. Compound 2.18 
was treated with potassium carbonate and methanol to cleave the acetate group. We were not 
able to deprotect the acetate group instead we obtained some unidentified compounds. 
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Another analogue was made following the same procedure. Compound 2.3 was treated 
with LDA to deprotonate C11 methyl group. Hence, treatment of 2.3 with LDA followed by a 
substituted benzaldehyde 2.20 gave alcohol 2.21. Alcohol was protected with acetate to give 
compound 2.22. Selective hydroxylation using BH3.THF at -20 0C followed by oxidation with 
hydrogen peroxide and hydrolysis of resultant borate with sodium hydroxide gave an inseparable 
mixture of two diastereomers alcohol 2.23. Alcohol 2.23 was mesylated using methanesulfonyl 
chloride. Mesylated product 2.24 was heated with adenine and DMA at 150 0C. Silica gel 
column chromatography resulted in impure 2.25 (Scheme 2.10). Further purification was carried 
out using HPLC but obtained very less compound and couldn’t analyze this further for structural 
characterization. 
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 Apart from adenine the other nucleic acid bases are guanine, thymine and cytosine. The 
intermediate bromide 2.9 was used to prepare CP2 on treatment with adenine. Following the 
same procedure, bromide 2.9 was treated with guanine, thymine and cytosine in presence of NaH 
and DMF as a solvent. The resulting compounds 2.26, 2.27, 2.28 and 2.29 were purified by 
column chromatography and HPLC. 
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2.4 Results and Discussion 
2.4.1 The death of MC65 cells depends on the production of Aβ 
MC65 cells conditionally express a partial APP fusion protein called SβC and die on the 
third day after transgene induction by removal of tetracycline (TC) from the media.22, 23, 25, 30 The 
death of MC65 results from the production of C99 and its derivatives. C99 is first expressed 
followed by subsequent appearance of other Aβ containing fragments of which 8KDa, 16.5KDa 
and 25KDa were the major species (Figure 2.7) (This work was done in Lee-Way Jin’s 
Laboratory, University of California, Davis).15, 23 
 
 
Figure 2.7 C99 and other fragments induced by removal of TC15 
 
 Pulse chase experiments failed to prove that CP2 did not affect the rate of C99 production. 
Then Aβ levels were measured in the conditioned media from cells (for 48 hrs) treated with 
drugs. Neither CP2 (10 μM) nor TP17 (10 μM) significantly altered the level of Aβ in 
conditioned media. By contrast γ-secretase inhibitor L-685,458 (2 μM) significantly reduced the 
amount of Aβ secreted in both MC65 cells (Figure 2.8)15 (This work was carried out by Lee-Way 
Jin Laboratory, University of California, Davis) and N2a-APPsw (Figure 2.9)15 (This work was 
done in Lee-Way Jin’s Laboratory, University of California, Davis) cells. Collectively this 
illustrates that CP2 does not affect Aβ production or degradation effectively. 
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Figure 2.8 MC65 cells with TC and without TC. CP2 and TP17 compounds were also tested15 
 
 
Figure 2.9 N2a-APPsw cells compared with control15     
 
 Treatments with L-685,458 blocked the death of TC-MC65 cells in a dose dependant 
manner, with an EC50 of ~110nm (Figure 2.10) (This work was done in Lee-Way Jin’s 
Laboratory, University of California, Davis) which clearly indicates that the generation of Aβ is 
necessary for toxicity.15 At the rescuing concentrations, L-685,458 significantly reduced or 
completely blocked the 16.5 kDa and 25 kDa in a dose dependant fashion (Figure 2.11)15 (This 
work was done in Lee-Way Jin’s Laboratory, University of California, Davis) clearly indicating 
that these bands are nothing but homo- and hetero oligomeric complexes of Aβ.15 This is also 
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proven by quantification of these bands by measuring the optical density of the bands by NIH 
image. 
 
 
 
 
 
Figure 2.10 Cell viability was assessed after 72 hrs of removal of TC in L-685,458 at different     
concentrations15 
 
 
Figure 2.11 Different concentrations of L-685,458 was added with TC removal, analyzed by 
western blot using 6E1015 
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 ELISA assays failed to detect Aβ in untreated cell homogenates, which clearly detected 
monomeric Aβ40 and trace amount of Aβ42 after formic acid extraction (Figure 2.12) (This 
work was done in Lee-Way Jin’s Laboratory, University of California, Davis).15 It was believed 
that during the process of homogenization Aβ oligomeric complexes (Aβ-OCs) were formed. To 
test this possibility MC65 cells were homogenized in presence of a dye, congo red. Thus it was 
proven that during the process of homogenization Aβ quickly aggregated into Aβ-OCs (Figure 
2.13) (This work was carried out by Lee-Way Jin Laboratory, University of California, Davis).15 
 
 
Figure 2.12 MC65 cells were homogenized with and without formic acid extraction15 
 
 
Figure 2.13 MC65 cells were homogenized in presence of Congo red and analyzed by western 
blot15      
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 Woltjer and coworkers proved that 8-kDa band mainly comprises of Aβ dimers.23 From 
the above experiments it is proven that 8-kDa band was not completely reduced either by L-
685,458 treatment or formic acid disaggregation, proves that this band is not fully composed of 
Aβ peptides.15 This band was not also recognized by antibody B994 (Figure 2.14) (This work 
was done in Lee-Way Jin’s Laboratory, University of California, Davis).15 So the composition of 
this band is not known, most likely this may be combination of Aβ dimers and COOH-terminal 
membrane fragment (CTF) ∆31, a caspase cleavage product of C99. When the proteins of TC-
MC65 cells were separated by tricine/SDS PAGE, C99 was recognized both by 6E10 and B994 
antibodies (Figure 2.14). Band C83, α-secretase cleavage product of C99 was not recognized by 
6E10. Surprisingly L-685,458 treatment increased the level of C83.15 
 
 
Figure 2.14 Comparison of cellular proteins. Analyzed with 6E10 and B994 antibodies15 
 
2.4.2 TP analogues protect MC65 cells in a structure dependent manner and CP2’s 
protective effect is intimately related to its inhibition of Aβ-OCs 
TP analogues protected MC65 cells with various potencies.24, 25  TPs were synthesized 
based on the structures of pyripyropene A, apotent acyl-CoA: cholesterol O-acyltransferase 
(ACAT) inhibitor and arisugasin, a potent acetylcholineesterase inhibitior.29 Both of them affect 
Aβ production and aggregation.31-33 Surprisingly TPs protect MC65 cells at concentrations 1000 
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fold lower than those required for ACAT and acetylcholineesterase inhibition. However we 
found out that CP2 2.2 was selected for further studies due to its high potency and low cellular 
toxicity. This CP2 is readily synthesized in 4 steps. CP2 protects MC65 cells at nanomolar 
concentrations (EC50 ≈0.15 μM). This CP2 contains both isomers 12-R and 12-S. They are 
unseparable even by HPLC. N9’ analogue of CP2 2.31 was less active (EC50 ≈3.0 μM) compared 
to CP2. The other isomer N10’-analogue 2.32 was not active at all. TP compound 2.33 was also 
inactive. CP1 also protected MC65 cells but less effective (EC50 ≈2.6 μM) than CP2. A graphical 
representation of MC65 cell survival over different concentrations of different TP compounds is 
shown in figure 2.15 (This work was done in Lee-Way Jin’s Laboratory, University of California, 
Davis).15 
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Figure 2.15 MC65 protection assay with different concentrations of different TP analogues15 
 We compared the effect of CP2, N9’-analogue and TP17 analogue on the accumulation 
of intracellular Aβ-OCs. Western blots demonstrated that only CP2 selectively reduces the levels 
of cellular Aβ-OCs (in a dose dependant manner) (Figure 2.17) (This work was done in Lee-Way 
Jin’s Laboratory, University of California, Davis) not N9’ analogue or TP17 (Figure 2.16). None 
of the drugs affected the levels of C99 and C83 (Figure 2.16 right panel). The western blots in 
figure 2.16 (This work was carried out by Lee-Way Jin Laboratory, University of California, 
Davis) demonstrated that 16.5 and 25 kDa bands were reduced when treated with 2 μM of CP2. 
“There was a one third reduction in p8 band similar to the effect of L-658,458 and formic acid 
disaggregation”.15 “This implies that CP2 treatment also resulted in diaggregation of Aβ 
isomers”.15 Figure 2.14 shows a comparison between the effect of CP2 and L-685,458. Since the 
effect of CP2 was not through inhibition of γ-sectretase as of L-685,458, so CP2 might interfere 
with the formation of Aβ-OCs. 
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Figure 2.16   MC65 cells treated with different TP analogues. Western blots were analyzed with 
6E10 and B994 antibodies.15 
 
Figure 2.17 MC65 cells were treated with different concentrations of CP2. Western blot was 
analyzed using 6E10 antibody15    
 
 Parallel immunocytochemical studies revealed that CP2 reduced the level of cytoplasmic 
Aβ-immunoreacive deposits whereas N9’ analogue and TP17 didn’t. There was no visible 
immunoreactivity seen in +TC cells. Twenty four hours after TC removal the cells showed 
cytoplasmic Aβ-immunoreacive deposits (Figure 2.18) (This work was done in Lee-Way Jin’s 
Laboratory, University of California, Davis).15 The experiment was followed by confocal 
microscopy. This confirms that CP2 prevents the formation of intracellular Aβ aggregates. It also 
suggests that Aβ-OCs, demonstrated by Western blots (Figure 2.17) may be the major 
constituents of the cytoplasmic deposits.15 
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Figure 2.18 MC65 cells were treated with TP17 and CP2 (2 μM). Arrows indicate the deposition 
of Aβ-immunoreactive coarses.15 
 
2.4.3 CP2 directly binds to Aβ and inhibits Aβ fibrilization 
The above results strongly suggest that one of the cellular targets of CP2, either directly 
or indirectly, is the intracellular Aβ containing aggregates and aggregation process. To determine 
the lipophilicity of CP2, we measured the octonol/water partition coefficient (POct) of CP2. A 
favourable POct value for membrane penetration is 10. The POct value for CP2 was 159, indicating 
its lipophilicity. According to Lipinski’s rule,34 CP2 has one hydrogen bond donor, seven 
hydrogen hydrogen bond acceptors, a MW of 393 and a calculated Log POct value of 2.2, so is 
predicted that CP2 has good adsorption and permeation properties. Therefore it is likely that CP2 
may permeate the cells and interact with intracellular accumulated Aβ.15 Also when MC65 cells 
were incubated with [14C]CP2, there is an accumulation of radioactivity inside the cells (Figure 
2.19) (This work was done in Lee-Way Jin’s Laboratory, University of California, Davis).15 
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Figure 2.19 Accumulation of CP2 inside the MC65 cells. The empty circles represent the cell 
surface CP2 and the dark circles represent the intracellular CP2.15 
 
Biacore’s surface plasma resonance spectroscopy (SPR) was used to know if CP2 
interacts with Aβ (this experiment was performed by Hui-Chuan Wu and Sandeep Rana). The 
binding of CP2 to Aβ1-40 and Aβ1-42 was clearly demonstrated, inspite of small responses due 
to small size of CP2. A real time biosensogram shown in figure 2.20 (This experiment was 
performed by Hui-Chuan Wu and Sandeep Rana) demonstrated that CP2 bound to the sensor 
CM5 chip immobilized with Aβ1-40, but not nonspecifically to the chip without immobilized 
Aβ1-40. “Approximately 1.5 equivalents of CP2, 0.46 equivalents of N9’-analogue, no TP17 
were found to bind one equivalent of Aβ1-40 respectively. Similarly, 1 equivalent of of CP2, 0.2 
equivalent of the N9’-analogue, but no TP17 were found to bind one equivalent of Aβ1-42 
respectively”.15 These results demonstrate that the SPR binding studies of TP compounds appear 
parallel to their MC65 protection activities. The kinetic analysis of sensograms is shown in the 
table 2.2 (This work was done in Lee-Way Jin’s Laboratory, University of California, Davis). 
CP2 shows high binding affinity to both Aβ40 and Aβ42 peptides. N9’-analogue shown an 
average binding and TP17 doesn’t show any binding towards Aβ peptides.15 
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Figure 2.20 TP compounds binding to Aβ 1-40 (all left panels) and Aβ 1-42 (all right panels) by 
SPR. Blue line is the response from the reference cell and the red line is the response from the 
experimental cell.15 
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Table 2.2 KD values for different TP compounds to Aβ peptides. NB = No binding15 
 
2.4.4 Atomic Force Microscopic (AFM) studies showing CP2 inhibits the Aβ 
aggregation 
Tapping mode AFM (Nanoscope IIIa SPM, Digital instruments Inc., SB, CA, USA) was 
used to obtain AFM images of the oligomerization and deoligomerization of Aβ peptides with 
CP2. Since Aβ40 aggregates at a slower rate than Aβ42, so Aβ40 was studied first. The Aβ40 
peptide was dissolved in double distilled water, diluted with 50 mM phosphate buffer saline 
solution, pH 7.4, and with and without 25% 2,2,2-trifluoroethanol (TFE). Two separate set of 
experiments were performed with and without CP2. The prepared samples were centrifuged to 
remove any un-dissolved aggregates. The aliquot (50 μL) was taken and loaded on freshly 
cleaved mica. The samples are air dried and washed with double distilled water to remove any 
presence of salts. The samples were air dried again and AFM images were taken. 
 
Atomic Force Microscopy (AFM) Studies of Aβ40 peptides 
 AFM images (All the AFM experiments were performed by Hui-Chuan Wu and Erik 
Pettersson) of Aβ40 peptides are shown in the following figures. Intially images were taken at 
different days without CP2 and TFE. 
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Figure 2.21 AFM image of Aβ40 in 50 mM phosphate buffer (no CP2) at day zero (upper panel). 
The heights and widths are shown in the bottom panel. 
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Figure 2.22 AFM image of Aβ40 in 50 mM phosphate buffer (no CP2) at day one (upper panel). 
The heights and widths are shown in the bottom panel (largest oligomer is 74 nm high and 400 
nm wide). 
 
 
Figure 2.23 AFM image of Aβ40 in 50 mM phosphate buffer (no CP2) at day three. Protofibrils 
and fibrils are formed and the lengths are 1μM. 
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Figure 2.24 AFM image of Aβ40 in 50 mM phosphate buffer (no CP2) at day 50. The material 
inside the solution is mainly fibrils and proto-fibrils. The largest fibril is 125 nm high and 1 μM 
wide. 
 
 The following figures show AFM images, taken at different days with 25% TFE and without 
CP2. 
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Figure 2.25 AFM image of Aβ40 in 50 mM phosphate buffer, 25% TFE (no CP2) at day zero 
(upper panel). The lower panel represents the size and width of the oligomers. 
 
 
Figure 2.26 AFM image of Aβ40 in 50 mM phosphate buffer, 25% TFE (no CP2) at day one. 
 
 
Figure 2.27 AFM image of Aβ40 in 50 mM phosphate buffer, 25% TFE (no CP2) at day three. 
Protofibrils and fibrils were formed. 
 
The following figures show AFM images, taken at different days without TFE and with one 
equivalent of CP2. 
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Figure 2.28 AFM image of Aβ40 in 50 mM phosphate buffer, in the presence of one equivalent 
of CP2 at day zero. The largest oligomer is about 30 nm high and 40 nm wide. 
 
 
Figure 2.29 AFM image of Aβ40 in 50 mM phosphate buffer, in the presence of one equivalent 
of CP2 at day one. The largest oligomer is about 35 nm high and 40 nm wide. 
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Figure 2.30 AFM image of Aβ40 in 50 mM phosphate buffer, in the presence of one equivalent 
of CP2 at day three. Formation of fibrils or protofibrils was not found. 
 
Figure 2.31 AFM image of Aβ40 in 50 mM phosphate buffer, in the presence of one equivalent 
of CP2 at day 50. No fibrils and protofibrils were found. Largest  sizes of oligomers are about 2 
nm high and 30 nm wide. 
 
The following figures show AFM images, taken at different days with 25% TFE and with one 
equivalent of CP2. 
 
Figure 2.32 AFM image of Aβ40 in 50 mM phosphate buffer, 25% TFE, in the presence of one 
equivalent of CP2 at day zero. The largest oligomers are about 10 nm high and 30 nm wide. 
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Figure 2.33 AFM image of Aβ40 in 50 mM phosphate buffer, 25% TFE, in the presence of one 
equivalent of CP2 at day one. The largest oligomers are about 15 nm high and 70 nm wide. 
 
 
Figure 2.34 AFM image of Aβ40 in 50 mM phosphate buffer, 25% TFE, in the presence of one 
equivalent of CP2 at day three. No fibrils and protofibrils were found. 
 
 From the above AFM images we can conclude that the rate of aggregation is slower in 
presence of TFE than without TFE.  In any case in presence of TFE and one equivalent of CP2, 
we never observed any fibrils and protofibrils or even presence of large oligomers. From this 
data we can conclude that CP2 inhibits the aggregation of Aβ40 peptides and possibly protect 
against MC65 cell death. 
 Similarly we studied the aggregation of Aβ42 in the presence and absence of CP2 using 
AFM. As we know that the Aβ42 aggregates much faster than Aβ40, so 50% TFE was added to 
decrease the rate of aggregation. Aβ42 peptide is a mixture of random coil, α-helix and β-sheet. 
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So Aβ42 peptide is dissolved in phosphate buffer and 50% TFE, pH 7.4, with and without one 
equivalent of CP2. AFM images were taken on day 1 and day zero. 
 The first three figures 2.35, 2.36 and 2.37 are the AFM images (All the AFM experiments 
were performed by Hui-Chuan Wu and Erik Pettersson) in the absence of CP2 in day zero and 
day one. The very next day we can see the formation of large oligomers and protofibrils. The 
next three images 2.38, 2.39, 2.40 are the AFM images in the presence of one equivalent of CP2 
in day zero and day one. After treatment with CP2 the largest oligomer was found to be in 40 nm 
size. 
 
 
 
Figure 2.35 AFM image of Aβ42 in 50%TFE in the absence of CP2 at day zero. The largest 
oligomer is about 60 nm size. 
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Figure 2.36 A zoom in AFM image of the above Aβ42 in 50%TFE in the absence of CP2 at day 
zero. 
 
Figure 2.37 AFM image of Aβ42 in 50% TFE in the absence of CP2 on day one. The arrows 
indicate the formation of protofibrils and large oligomers. 
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Figure 2.38 AFM image of Aβ42 in 50% TFE in the presenc of one equivalent of CP2 on day 
zero. The size of the oligomers is about 10-50 nm. 
 
 
Figure 2.39 AFM image of Aβ42 in 50% TFE in the presence of one equivalent of CP2 on day 
one. The oligomers are about 10 nm-40 nm in sizes. The formation of protofibril is not observed. 
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Figure 2.40 A zoom in image of the above AFM image of Aβ42 in 50% TFE in the presence of 
one equivalent of CP2 on day one. The arrow shows the largest oligomer of size 40 nm. 
 
In the presence of one equivalent of CP2, the Aβ oligomers remained the same or 
decreased slightly to 40 nm and only 5% of peptide aggregated. In conclusion the aggregation of 
Aβ42 peptide was inhibited and there is no formation of fibrils and protofibrils was observed. 
To test the toxicity of CP2, Aβ42 oligomers was applied to primary cortical neurons.15 
Aβ42 oligomers showed low levels of toxicity at 10 nM and showed a considerable amount of 
toxicity starting from 50 nM (Figure 2.41) (This work was carried out by Lee-Way Jin 
Laboratory, University of California, Davis). But unaggregated Aβ42 showed no significant 
toxicity.15 Also the figure 2.42 (This work was carried out by Lee-Way Jin Laboratory, 
University of California, Davis) shows how CP2 blocks the toxicity when co administered Aβ42 
oligomers. So CP2 not only protects the cell intracellularly but also blocks the toxicity of the 
extacellular applied Aβ oligomers.15  
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Figure 2.41 Cortical neurons were treated with different concentrations of Aβ42 oligomers. Data 
is shown as percentage viability after 48 hr treatment with Aβ42 oligomers.15 
 
 
Figure 2.42 Cortical neurons treated with Aβ monomers (M) and oligomers (O) in presence of 
CP2 (50 nM)and TP17 (50 nM).15 
 
It is believed that protein aggregation leads to many neurodegenerative diseases. 
Different types of proteins are responsible for different types of diseases as shown in table 2.1.6 
The formation of Aβ fibrils in the brain lead to neuron death. With the increase in number of 
deaths every year, it is very important to address the mechanism of Aβ aggregation which 
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induces toxicity and eventually leads to patient’s death. To study the mechanism we used MC65 
cells, human neuroblastoma cells as a model to study the aggregation and toxicity. We 
synthesized different TP analogues to test the activity on MC65 cells.15 Compound 2.2 (CP2), a 
TP analogue was studied extensively in this regard. We prepared CP2 in four steps starting form 
readily available compounds perillaldehyde and pyrone. 
CP2 is a hydrogen donor and a good hydrogen acceptor, with molecular weight 393 and 
an octanol/water partition coefficient of 159. So according to Lipinski rules34 CP2 is predicted to 
have good permeation property. This was also proved by radio labeling studies (Figure 2.19) and 
CP2 favors the blood brain barrier passage. We demonstrated that, the production of Aβ protein 
is responsible for the death of MC65 cells. It was also proven that the CP2 protects the cell death 
and inhibits the generation of Aβ oligomers (by SPR and AFM studies). 
It was reported that some azodyes like congo red15, 35, 36 can also inhibit the Aβ 
aggregation. Physical and structural aspects of these compounds will not allow them to permeate 
into the cells and also exhibit cell toxicity. Compounds like curcumin15, 37 also inhibit the 
formation of Aβ oligomers. Unlike, above compounds CP2 is a small molecule that exhibit same 
properties without showing any toxicity in our assays. 
CP2 has a structural scaffold that is accessible for optimization. Small molecules, 
compared to macromolecules such as β-sheet breaker peptides, have the advantage of lower cost, 
higher membrane permeability, higher stability, and high resistance to degradation. This 
versatility of small compounds is important for studying protein aggregation diseases like AD. 
As shown in figure 2.6 there are number of sites where modifications on CP2 can be performed. 
To understand the mechanism of intraneuronal Aβ aggregation and toxicity it is necessary to 
have a structure activity relationship study on CP2 derivatives.15 Apart form CP2 recently we 
synthesized quinoline deivatives, structurally different to that TP compounds which also exhibits 
the inhibition of aggregation. The synthesis of the compounds 2.30, 2.31, 2.32 is not discussed in 
this thesis. These are a series of quinoline compounds where they have varied activity. Similar 
studies on these compounds are yet to be performed. 
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2.5 Experimental 
 
General Methods. Nuclear Magnetic Resonance (NMR) spectra were recorded on a 400 MHz 
and 100 MHz Varian spectrometer in CDCl3 unless otherwise specified. The chemical shifts are 
given in parts per million (ppm) from downfield from tetramethylsilane as internal standard. 
Coupling constants (J) are given in hertz. TLC analyses were performed on thin-layer analytical 
plates from Aldrich. All the reactions were performed in argon atmosphere unless otherwise 
specified. Silical gel (200~400 mesh) from Natland corporation was used for column 
chromatographic separations. Solvents like THF and diethyl ether were distilled over sodium and 
benzopheneone, methylene chloride was distilled over CaH2 and finally benzene and toluene 
were distilled over LiAlH4. 
 
(5aS,7S)-7-Isopropenyl-3-methyl-1H,7H-5a,6,8,9-tetrahyro-1-oxopyranol[4,3-b][1] 
benzopyran (2.3) (SB-8-65)24, 29 
O
O
O
H
1 3
4
5a
7
 
 
 To a solution of 5 g (0.03968 mol) of 2.5 in 200 mL of ethyl acetate under argon at room 
temperature was added 6.55 g (0.04367 mol) of aldehyde 2.4 and 2.28 g (0.01984 mol) of L-
proline. The reaction mixture was heated to reflux for 5 hrs. The reaction mixture was washed 
with water and brine. The organic layer was extracted with ethyl acetate. The organic layer was 
dried with anhydrous sodium sulfate, filtered and concentrated. Column chromatographic 
separation (on silica gel) using mixture of hexane and ethyl acetate (3:1 v/v) afforded 9.1 g of 
yellow solid, 2.3 in 78% yield. Purification was also performed by recrystillazation using ethyl 
acetate as a solvent. [α]22D = +31.90 (c 0.75, CHCl3); 1H NMR (CDCl3) δ 6.1 (s, 1 H, C10 H), 
5.72 (s, 1 H, C4 H), 5.1 (dd, J = 11 Hz, J = 5 Hz, 1 H, C5a H), 4.75 (m, 1 H, =CH), 4.73 (m, 1 H, 
=CH), 2.48 (ddd, J=14 Hz, J = 4 Hz, J = 2.4 Hz, 1 H), 2.22-2.02 (m, 3 H, CH2), 2.19 (s, 3 H, C4-
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Me), 1.88-1.72 (m, 2 H, CH2), 1.74 (s, 3 H, MeC=), 1.31 (ddd, J = 25  Hz, J = 12.8 Hz, J = 4 Hz, 
1 H); 13C NMR δ 163.4, 162.6, 161.7, 147.9, 132.3, 109.8, 109.6, 99.9, 97.5, 79.4, 43.6, 40.0, 
32.5, 32.1, 20.9, 20.3. 
 
(5aS,7S)-7-[(1R) and (1S)-2-Hydroxy-1-methylethyl]-3-methyl-1H,7H-5a,6,8,9-tetrahyro-1-
oxopyranol[4,3-b][1] benzopyran (2.6) (SB-4-100)24, 29 
O
O
O
H
OH  
To a solution of 2.13 g (8.256 mmol) of 2.3 in 30 mL THF was added 8.25 mL (8.256 mmol) of 
1 M BH3.THF complex at -25 0C. After stirring the solution at -25 0C for 12 hours, 17 mL of 
0.5% aqueous NaOH and 7 mL of 30% hydrogen peroxide were added at 0 0C. The solution was 
stirred at 0 0C for 4 hours and diluted with water and washed with dichloromethane three times. 
The organic layer was washed with brine, dried over anhydrous sodium sulfate and concentrated 
to dryness. The resulting solution was applied to silica gel column chromatography using 
gradient mixture of hexane and ethyl acetate afforded 1.25 g (80% yield; based on amount of 
reacted 2.3) of 2.6 as a mixture of two diastereomers at C12 and 23 % recovery of starting 
material 2.3. 1H NMR (CDCl3) δ 6.08 (s, 1 H, C4 H), 5.71 (s, 1 H, C10 H), 5.07 (t, J = 5.2 Hz, 1 
H, C5a H), 3.58 (m, 2 H, CH2O), 2.46 (m, 1 H), 2.19 (s, 3 H, Me), 2.11 (m, 2 H), 1.73-1.51 (m, 3 
H), 1.16 (m, 2 H), 0.92 (d, J = 7 Hz, 3 H, Me); 13C NMR δ 163.5, 162.8, 161.6, 133.0, 109.0, 
100.0, 97.4, 79.7, 79.6, 65.6, 39.9, 39.8, 39.4, 37.2, 37.1, 36.9, 32.4, 32.3, 31.1, 30.4, 28.5, 20.1, 
13.2, 13.1. 
 
(5aS,7S)-7-[(1R) and (1S)-2-(Methanesulfonyloxy)-1-methylethyl]-3-methyl-1H,7H-5a,6,8,9-
tetrahyro-1-oxopyranol[4,3-b][1] benzopyran (2.7) (SB-4-104)24, 29 
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O
O
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OMs  
To a solution of 600 mg (2.1739 mmol) of 2.6 in 18 mL of methylene chloride 0.91 mL of 
triethylamine was added at 0 0C. The resulting solution was stirred at 0 0C for 10 minutes. To this 
solution 0.253 mL (3.261 mmol) of methane sulfonyl chloride was added at 0 0C. The resulting 
solution was stirred at 0 0C for 3 hours and diluted with water. The progress of the reaction was 
monitored using TLC using hexane and diethyl ether (2:1 v/v) as a developing solvent. The 
mixture was extracted with methylene chloride. The organic layer was washed with aqueous 
solution of sodium bicarbonate and brine, dried over sodium sulfate. Column chromatographic 
separation on silica gel using mixture of hexane and diethyl ether (2:1 v/v) afforded 550 mg of 
2.7 in 91% yield as a mixture of two diastereomers. 1H NMR (CDCl3) δ 6.08 (s, 1 H, C4 H), 5.71 
(s, 1 H, C10 H), 5.06 (m, 1 H, CHO), 4.14 (m, 2 H, CH2O), 3.03 (s, 3 H, MeS), 2.49 (d, J = 2.8 
Hz, 1 H), 2.19 (s, 3 H, Me), 2.14-1.11 (m, 7 H), 0.98 (d, J = 6.8 Hz, 3 H, Me); 13C NMR δ 163.2, 
162.4, 161.7, 132.1, 109.6, 105.2, 99.8, 79.2, 79.1, 72.3, 38.9, 37.5, 37.4, 37.3, 37.2, 36.9, 32.2, 
32.1, 30.8, 28.6, 20.2, 13.3, 13.2. 
 
(5aS,7S)-7-[(1R) and (1S)-2-(N9-Adenyl)-1-methylethyl]-3-methyl-1H,7H-5a,6,8,9-
tetrahyro-1-oxopyranol[4,3-b][1] benzopyran (2.8) and (5aS,7S)-7-[(1R) and (1S)-2-(N3-
adenyl)-1-methylethyl]-3-methyl-1H,7H-5a,6,8,9-tetrahyro-1-oxopyranol[4,3-b][1] 
benzopyran (2.2) (SB-4-105)24, 29 
 
O
O
O
H
2.2
N
N N
N
NH2
O
O
O
H
N
NN
N
NH2
9'3'
2.8  
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To a solution of 550 mg (1.554 mmol) of mesylate 2.7 in 10 mL of N,N-dimethyl acetamide 
(DMA) was added 209.7 mg (1.554 mmol) of adenine. The reaction mixture was heated to 150 
0C for 8 hours. Then the vessel was cooled to room temperature and was added 1.554 mmol of 
sodium bicarbonate. Then the DMA in the reaction mixture was vacuum distilled to obtain a 
brown residue. Without any further workup the residue was made to dissolve in minimum 
amount of methanol (2 mL) and directly applied to silica gel Column chromatography. A 
mixture of chloroform and methanol (4:1 v/v) was used as eluent to give 4 % yield of 2.8 and 43 
% yield of 2.2. The obtained product was not pure after column chromatographic separation. So 
the combined fractions consisting of compound (2.2) (decided based on the proton NMR of the 
fractions after column chromatographic separation) were subjected to HPLC (Jupiter C18, 10-μ 
column (Phenomenex, Torrance, CA, USA)) separation. The running solvent system was water 
and acetonitrile with 0.1% trifluoroacetic acid (TFA). We ran several programs with varying 
amounts of solvents from both the pumps with a flow rate of 4 mL/minute. Finally were we able 
to separate both the compounds 2.8 and 2.2. The obtained fractions were collected separately and 
lyophilized to obtain compounds 2.2 and 2.8 as TFA salts. We are uncertain about the number of 
TFA molecules adhering to one molecule of each compound. 1H NMR of 2.2 (CDCl3) δ 8.07 (s, 
1 H, C8’H of adenine), 7.98 and 7.97 (2s, 1 H, C2’H of adenine; 2diastereomers), 6.10 (s, 1 H, 
C10 H), 5.72 and 5.71 (2s, 1 H, C4 H), 5.02 (m, 1 H, C5a H), 4.50 (dd, J = 14, 7 Hz, 1 H, CHN), 
4.08 (2dd, J = 14 Hz, J = 8 Hz, 1 H, CHN), 2.46 (m, 2 H), 2.20 and 2.19 (2s, 3 H, Me), 2.10-1.22 
(m, 6 H), 0.91 (d, J = 7 Hz, 3 H, Me); 13C NMR δ 163.2, 163.1, 162.4, 161.7, 154.4, 154.0, 150.7, 
142.3, 131.7, 131.6, 121.0, 199.8, 99.7, 97.3, 79.0, 78.8, 54.5, 54.4, 38.9, 38.1, 38.0, 37.1, 36.9, 
36.1, 32.0, 31.9, 30.7, 27.6, 20.1, 13.3, 13.2.  1H NMR of 2.8 (CDCl3) δ 8.36 (s, 1 H, C2’ H), 
7.78 (s, 1 H, C8’ H), 6.09 (s, 1 H, C4 H), 5.89 (bs, 2 H, NH2), 5.72 (s, 1 H, C10 H), 5.01 (m, 1 H, 
C5a H), 4.24 (dd, J = 14 Hz, J = 7 Hz, 1 H, CHN), 4.01 (dd, J = 14 Hz, J = 7 Hz, 1 H, CHN), 2.5-
1.2 (m, 8 H), 2.19 (s, 3 H, Me), 0.90 (d, J = 7 Hz, 3 H, Me); 13C NMR δ 163.4, 162.7, 161.9, 
155.6, 153.5, 150.6, 140.9, 132.1, 119.8, 109.9, 99.9, 97.5, 79.4, 79.2, 47.9, 39.3, 38.4, 38.3, 38.1, 
38.0, 36.2, 32.3, 32.1, 31.1, 27.8, 20.3, 13.8. 
 
(5aS,7S)-7-[(1R) and (1S)-2-Bromo-1-methylethyl]-3-methyl-1H,7H-5a,6,8,9-tetrahyro-1-
oxopyranol[4,3-b][1] benzopyran (2.9) (SB-8-16)38 
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O
O
H
Br  
 
To a solution of 500 mg (1.825 mmol) of 2.6, 956 mg (3.65 mmol) of triphenylphosphine and 10 
mL of methylene chloride was added. The reaction mixture was cooled to 0 0C. 1.52 g (4.56 
mmol) of carbon tetrabromide was added in portions to this reaction mixture.38 The reaction was 
stirred at 0 0C for half an hour. Then the solvent was evapourated using rotavapor. Then the 
brown residue was applied to the column directly without any aqueous workup. Column 
chromatographic separation on silica gel using mixture of hexane and diethyl ether (1:1 v/v) 
afforded 90% of 2.9. 1H NMR of 2.9 (CDCl3) δ 6.09 (s, 1 H, C4 H), 5.71 (s, 1 H, C10 H), 5.08 
(m, 1 H, C5a H), 3.41 (d, J = 4.4 Hz, 2 H, CH2Br), 2.46 (m, 1 H), 2.19 (s, 3 H, Me), 2.11 (m, 2 
H), 1.73-1.51 (m, 3 H), 1.16 (m, 2 H), 1.03 (d, J = 7 Hz, 3 H, Me); 13C NMR δ 163.3, 162.5, 
161.7, 132.3, 109.5, 99.8, 97.5, 79.34, 79.21, 39.6, 39.5, 39.1, 38.83, 38.80, 36.7, 32.17, 32.10, 
30.9, 28.7, 20.2, 15.8.  
 
(5aS,7S)-3-(2-Hydroxyethyl)-7-isopropenyl-1H,7H-5a,6,8,9-tetrahydro-1-oxopyrano[4,3-
b][1]benzopyran (2.10) (SB-7-106) 
O
O
O
H
OH
 
To a solution of 0.4 mL of diisopropylamine in 28 mL of THF was cooled to -20 0C. To this 
solution 1.8 mL of 1.6 M n-Buli was added and stirred for 30 minutes. Thus obtained solution is 
the freshly prepared LDA and the reaction vessel is maintained at -20 0C to reduce the 
decomposition. In another flask, to a solution of 250 mg (0.969 mmol) of 2.3 in 5 mL THF was 
cooled to -78 0C. To this solution 19.4 mL (1.9372 mmol) of freshly prepared LDA was added 
via syringe. After five minutes of stirring at -78 0C the solution turned deep blue in color 
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indicating the formation of anion. This solution was stirred at -78 0C for 2 hours. In another flask 
a suspended solution of 290 mg (9.6899 mmol) of paraformaldehyde in 10 mL THF was taken 
and cooled to 0 0C. The anion formed in another flask is transferred to the paraformaldehyde-
THF mixture via cannula and allowed to stir at 0 0C and slowly warmed to room temperature. 
The color of the solution turned reddish brown after reaching to room temperature. The reaction 
mixture was washed with water and extracted using methylene chloride. The organic layer was 
washed with aqueous sodium bicarbonate solution and brine, dried over anhydrous sodium 
sulfate, filtered and concentrated. Column chromatographic separation on silica gel using 
mixture of hexane and diethyl ether (1:1 v/v) gave a moderate yield 28% of 2.10 and 15% of 
starting material 2.3 was recovered. [α]D23 = +23.7o (C 3.5, CHCl3); 1H NMR CDCl3 δ  6.06 (s, 1 
H), 5.86 (s, 1 H), 5.11 (dd, J = 11 Hz, J = 4.4 Hz, 1 H, C5a H), 4.75 (s, 1 H, =CH2), 4.73 (s, 1 H, 
=CH2), 3.90 (t, J = 6.2 Hz, 2 H, CH2O), 2.69 (t, J = 6.2 Hz, CH2), 2.48 (m, 1 H), 2.20 ~ 1.70 (a 
series of m, 5 H), 1.73 (s, 3 H, Me), 1.34 ~ 1.25 (m, 1 H); 13C NMR δ 163.3, 162.1, 148.0, 132.8, 
109.9, 109.1, 101.1, 98.2, 79.6, 59.6, 43.6, 40.0, 37.3, 32.6, 32.1, 30.5, 20.9. HRMS calculated 
for C17H21O4 (M+H) 289.1440, found 289.1411. 
 
(5aS,7S)-3-(2-Acetoxyoxyethyl)-7-isopropenyl-1H,7H-5a,6,8,9-tetrahydro-1-oxopyrano[4,3-
b][1]benzopyran (2.14) (SB-8-29) 
O
O
O
H
OAc
 
 
To a solution of 202 mg (0.7014 mmol) of 2.10 in 3 mL of distilled pyridine was added 143 mg 
(1.402 mmol) of acetic anhydride at 0 0C. The reaction mixture was stirred at 0 0C for 7 hours. 
The progress of the reaction was monitored using TLC and diethyl ether was used as a 
developing solvent. The reaction mixture was washed with water and extracted with ethyl acetate. 
The organic layer was washed with 1 M HCl, aqueous sodium bicarbonate and brine, dried over 
anhydrous sodium sulfate and concentrated to dryness under vacuum. Column chromatographic 
separation on silica gel using diethyl ether afforded 140 mg of 2.14 in 62% yield. [α]D23 = +16.9o 
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(C 0.15, CHCl3); 1H NMR CDCl3 δ 6.10 (s, 1 H), 5.79 (s, 1 H), 5.13 (dd, J = 11.2 Hz, 4.8 Hz, 1 
H, C5a H), 4.75 (s, 1 H, =CH2), 4.73 (s, 1 H, =CH2), 4.33 (t, J = 6.4 Hz, 2 H, CH2O), 2.76 (t, J = 
6.4 Hz, CH2), 2.48 (m, 1 H), 2.20 ~ 1.70 (m, 5 H), 1.74 (s, 3 H, Me), 1.28 (qd, J = 12.8, 4 Hz, 1 
H); 13C NMR δ 170.9, 163.0, 160.9, 147.9, 132.9, 110.0, 109.6, 100.8, 98.5, 79.6, 60.8, 43.6, 
40.0, 33.6, 32.5, 32.1, 30.5, 20.1, 20.9. HRMS calculated for C19H23O5 (M+H) 331.1545, found 
331.1536. 
 
(5aS,7S)-3-(2-Acetoxyethyl)-7-(2-hydroxy-1-methylethyl)-1H,7H-5a,6,8,9-tetrahydro-1-
oxopyrano[4,3-b][1]benzopyran (2.15) (SB-8-34) 
O
O
O
H
OAc
OH  
 
To a solution of 143 mg (0.433 mmol) of 2.14 in 3 mL THF under argon was added 0.43 mL 
(0.433 mmol) of 1 M BH3.THF and the solution was stirred at -78 0C  for 30 minutes and stirred 
at -20 0C for two days. To the solution at 0oC, 1 mL of water, 0.5 m of 0.1% NaOH aqueous 
solution, and 0.5 mL of 30% H2O2 were added, and the resulting solution was stirred for 1 h. The 
solution was washed with water and extracted with methylene chloride. The organic layer was 
washed with aqueous solution of ammonium chloride and brine. The residue obtained after 
drying was applied to silica gel column chromatography. Diethyl ether was used as a solvent to 
give 72 mg of 2.15 in 56% yield along with 14% recovery of starting material 2.14. 1H NMR 
CDCl3 δ 6.07 (s, 1 H), 5.78 (s, 1 H), 5.10 (m, 1 H, C5a H), 4.32 (t, J = 6.2 Hz, 2 H, CH2O), 3.56 
(m, 2 H, CH2OH) 2.76 (t, J = 6.2 Hz, CH2), 2.47 (m, 1 H), 2.17 ~ 1.10 (m, 7 H), 0.91 (d, J = 7 Hz, 
1 H); 13C NMR δ 170.9, 163.0, 160.9, 133.4, 118.1, 109.3, 100.8, 98.5, 79.9, 66.0, 60.8, 40.2, 
39.5, 37.6, 37.5, 37.3, 33.6, 31.2, 21.0. HRMS calculated for C19H25O6 (M+H) 349.1651, 
found 349.1649. 
 
(5aS,7S)-3-(2-Acetoxyethyl)-7-[(2-methanesulfonyloxy)-1-methylethyl]-1H,7H-5a,6,8,9-
tetrahydro-1-oxopyrano[4,3-b][1]benzopyran (2.17) (SB-8-48) 
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O
O
O
H
OAc
OMs  
To a solution of 85 mg (0.2442 mmol) of 2.15 in 3 mL of methylene chloride was added 0.109 
mL (0.7326 mmol) of triethylamine at 0 0C. To the above solution 28 μL (0.3664 mmol) of 
methanesulfonyl chloride was added at 0 0C, the resulting mixture was stirred at room 
temperature for 3 hours. The reaction mixture was washed with water and extracted with 
methylene chloride. The organic layer was washed with aqueous solution of sodium bicarbonate 
and brine, dried over anhydrous sodium sulfate and concentrated to dryness under vacuum. 
Column chromatographic separation on silica gel using diethyl ether as a solvent afforded 94 mg 
of 2.17 in 90% yield. 1H NMR CDCl3 δ 6.05 (s, 1 H), 5.76 (s, 1 H), 5.07 (m, 1 H, C5a H), 4.29 (t, 
J = 6.3 Hz, 2 H, CH2O), 4.10 (m, 2 H, CH2OS), 3.00 (s, 3 H, CH3S), 2.73 (t, J = 6.3 Hz, CH2), 
2.47 (d, J = 14 Hz, 1 H), 2.17 ~ 1.10 (m, 7 H), 2.02 (s, 3 H, CH3CO), 0.96 (d, J = 7 Hz, 1 H); 13C 
NMR δ 170.9, 162.9, 162.3, 161.1, 132.7, 109.7, 100.7, 98.4, 79.4, 72.3, 60.8, 39.1, 37.6, 37.5, 
37.4, 33.6, 32.3, 30.9, 13.3. HRMS calculated for C20H27O8S (M+H) 427.1426, found 427.1434. 
 
(5aS,7S)-3-(2-Acetoxyethyl)-7-[(1R) and (1S)- 2-(N3-adenyl)-1-methylethyl]-1H,7H-5a,6,8,9-
tetrahydro-1-oxopyrano[4,3-b][1]benzopyran (2.18) (SB-8-50) 
 
O
O
O
H
OCOCH3
N
N N
N
NH2
3'
 
To a solution of 94 mg (0.22 mmol) of 2.17 in 1.5 mL of DMA was added 33 mg (0.2442 mmol) 
of adenine and the resulting mixture was heated to 150 0C for 7 hours. The reaction mixture was 
cooled to room temperature and 50 mg (0.59 mmol) of sodium bicarbonate was added and DMA 
was distilled out under reduced pressure to obtain a brown residue. This residue was made to 
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dissolve in minimum amount of methanol (2 mL) and applied to column directly. Column 
chromatographic separation on silica gel using mixture of chloroform and methanol (4:1 v/v) 
afforded 5 mg of 2.18 in low yields. The obtained product after column chromatographic 
separation was not pure. So we resorted to HPLC (Jupiter C18, 10-μ column (Phenomenex, 
Torrance, CA, USA)) to obtain pure compound. The running solvent system was water and 
acetonitrile with 0.1% trifluoroacetic acid (TFA). The flow rate was maintained at 4 mL/minute. 
The obtained fractions were lyophilized to obtain pure 2.18 as a TFA salt. The number of TFA 
molecules adhering to compound 2.18 remained uncertain. 1H NMR CDCl3 δ 8.07 (s, C8’H of 
adenine), 8.01 & 8.00 (2s, 1 H, C2’H of adenine; 2 diastereomers), 6.10 (s, 1 H, C10H), 5.79 & 
5.78 (2s, 1 H, C4 H), 5.05 (m, 1 H, C5a H), 4.54 (2dd, J = 13.5 Hz, J = 6.5 Hz, 1 H, CHN; 2 
diastereomers), 4.34 & 4.33 (2t, J = 6.2 Hz, 2 H, CH2O; 2 diasteromers), 4.07 (dd, J = 13.5, J = 8 
Hz, 1 H, CHN), 2.78 & 2.76 (2t, J = 6.2 Hz, 2 H, CH2; 2 diastereomers), 2.07 & 2.06 (2s, 3 H, 
Me; 2 diastereomers), 2.60 ~ 1.22 (m, 8 H), 0.91 (d, J = 7.0 Hz, 3 H, Me). 13C NMR δ 182.0, 
181.6, 164.8, 163.3, 161.1, 155.8, 152.9, 148.0, 141.6, 131.1, 129.6, 129.1, 121.3, 100.7, 79.1, 
78.9, 63.8, 59.2, 50.5, 33.6, 29.9, 21.1, 15.1. HRMS calculated for C24H28N5O5 (M+H) 466.2090, 
found 466.2081. 
 
(5aS,7S)-7-[(1R) and (1S)-2-(N1-Cytosinyl)-1-methylethyl]-3-methyl-1H,7H-5a,6,8,9-
tetrahyro-1-oxopyranol[4,3-b][1] benzopyran (2.26) (LZ-2-73) 
 
O
O
O
H
N N
NH2
O
1
2 3
4
5
6
 
To a solution of 100 mg (0.295 mmol) of 2.9 in 3 mL of DMF was added 13 mg of sodium 
hydride and 36 mg (0.3245 mmmol) of cytosine. The resulting solution was stirred at room 
temperature for 12 hours and then heated to 80 0C and stirred for 20 hours. Then the reaction 
mixture was cooled to room temperature and 9 μL of acetic acid was added to the reaction 
mixture. DMF was distilled out under reduced pressure to obtain a brown residue which was 
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loaded on to a silica gel column chromatography without any aqueous workup. Mixture of 
chloroform and methanol (4:1 v/v) was used as an eluent to give 13 mg of 2.26 in 12 % yield. 
Other fractions were difficult to characterize.  1H NMR CDCl3 δ 7.17-7.19 (4 s, C5 H and C6 H 
of cytosine), 6.07 (s, 1 H, C10 H), 5.71 and 5.72 (2s, 1 H, C4 H), 5.05 (m, 1 H, C5a H), 3.95 (m, 
1 H, CHN), 3.37 (m, 1 H, CHN), 2.19 (s, 3 H, Me), 2.60 ~ 1.22 (a series of m, 8 H), 0.87 (d, J = 
2 Hz, 3 H, Me). 13C NMR (CD3OD) δ 166, 165.5, 163.9, 151.3, 137, 134.8, 109.6, 101.2, 94.5, 
80.98, 80.83, 67.1, 54.5, 40.2, 39.5, 38.3, 37, 33.1, 32, 29.5, 19.9, 15.6, 13.7. 
 
(5aS,7S)-7-[(1R) and (1S)-2-(N1-Thymineyl)-1-methylethyl]-3-methyl-1H,7H-5a,6,8,9-
tetrahyro-1-oxopyranol[4,3-b][1] benzopyran (2.28) (SB-9-95) 
O
O
O
H
HN
NO
O
1
3 5
6
 
To a solution of 100 mg (0.29 mmol) of 2.9 in 5 mL of DMF was added 13 mg of sodium 
hydride and 40 mg (0.319 mmol) of thymine. The resulting solution was stirred at room 
temperature for 24 hours. To this reaction mixture 17.4 μL of acetic acid was added. DMF was 
distilled out under reduced pressure to obtain a brown residue. This brown residue was loaded on 
to a silica gel column chromatography without any aqueous workup. Column chromatographic 
separation using mixture of chloroform and methanol (4:1 v/v) gave 22 mg (20 % yield) of 2.28. 
The remaining fractions obtained after column chromatography were difficult to characterize. 1H 
NMR CDCl3 δ 6.9 (s, 1 H, C6 H of thymine), 6.09 (d, J = 5.2 Hz, 1 H, C10 H), 5.7 (s, 1 H, C4 
H), 5.04 (m, 1 H, C5a H), 3.9 (m, 2 H, CH2N), 2.60 ~ 1.22 (m, 8 H), 2.19 (s, 3 H, Me), 1.94 (s, 3 
H, Me of Thymine), 0.82-0.91 (4s, 3H, Me from two diastereomers). 13C NMR (CDCl3) δ 181.0, 
178.8, 150.1, 141.6, 140, 134.5, 109.9, 109.5, 99.9, 99.9, 97.1, 72.1, 45.3, 39.2, 36.1, 32.2, 28.3, 
20.3, 13.4. 
 
(5aS,7S)-7-[(1R) and (1S)-2-(N9-Guanineyl)-1-methylethyl]-3-methyl-1H,7H-5a,6,8,9-
tetrahyro-1-oxopyranol[4,3-b][1] benzopyran (2.29) (SB-9-93) 
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To a solution of 200 mg (0.59 mmol) of 2.9 in 8 mL of DMF was added 26 mg of sodium 
hydride and 107 mg (0.71 mmol) of guanine. The resulting solution was stirred at room 
temperature for 16 hours. DMF was distilled out under reduced pressure to obtain a brown 
residue, which was loaded on to a silica gel column chromatography. No aqueous workup was 
performed. A mixture of chloroform and methanol (4:1 v/v) was used as an eluent to give 35 mg 
(15% yield) of title compound 2.29. 1H NMR CDCl3 δ 7.54 (bs, 1 H, C8 H of guanine), 6.11 (s, 1 
H, C10 H), 5.7 (s, 1 H, C4 H), 5.02 (m, 1 H, C5a H), 3.99 (m, 2 H, CH2N), 2.60 ~ 1.22 (m, 8 H), 
2.08 (s, 3H, Me), 0.87 (s, 3 H, Me). 13C NMR (CD3OD) δ 176.9, 162.0, 161.01, 155, 157, 134.9, 
109.6, 101.3, 84.6, 80.9, 67.1, 45.0, 39.4, 29.9, 29.3, 29.2, 22.6, 19.9, 15.6.  
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Appendix 
 
1H NMR SPECTRA AND 13C NMR SPECTRA 
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